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SUMMARY
Introduction
The renin-angiotensin system is activated in acute severe asthma although the 
mechanism for is unclear. Angiotensin II is a weak bronchoconstrictor, potentiates the 
effects of other bronchoconstrictors and can be formed by inflammatory proteases. In 
vitro, angiotensin II is a growth promoter for human airway smooth muscle cells. The 
insertion/deletion polymorphism of the ACE gene accounts for variation in ACE activity 
and the deletion allele may be more frequent in asthmatics. In view of these facts, 
further clarification of the role of the renin-angiotensin system in asthma is required.
Aims
This thesis examines the factors causing activation of the renin-angiotensin 
system in acute severe asthma, the role of the ACE gene polymorphism, the putative 
effects of angiotensin II on the action of histamine in the human airway both in vitro 
and in vivo, the effects of angiotensin II on rat airway smooth muscle cell growth in 
vivo and seeks evidence for the existence of a local renin-angiotensin system in the 
human lung.
1. Mechanism of Activation of the Renin-Angiotensin System in Asthma
Clinical data were obtained from 40 acute asthmatic hospital admissions and 
correlated with plasma levels of renin and angiotensin II. The genotype for the ACE 
gene polymorphism was determined in this group, a group of 20 non-asthmatic acute 
medical hospital admissions and 78 healthy volunteers to allow comparison of allele 
frequencies and correlation with both ACE activity and angiotensin II levels.
Plasma renin and angiotensin II were elevated in some, but not all of the acute 
asthmatics and no correlation was found with any of the parameters measured. The DD 
homozygote for the ACE gene polymorphism had the highest ACE activity in all groups 
measured. There was a non-significant trend towards an increased frequency of the 
deletion allele in asthmatics compared with normal controls. An unexpected finding was 
the increased ACE activity for the DD and ID genotypes found in acute hospital 
admissions compared with healthy controls. The clinical significance of this is 
uncertain.
2. Effect of Angiotensin II on Histamine-Induced Bronchoconstriction
The effect of angiotensin II on histamine-induced contraction of human 
bronchial rings in vitro was examined by constructing concentration-response curves to 
histamine (10'9M - 3x1 O^M) in the presence and absence of sub-threshold doses of 
angiotensin II (10'7M - 10'6M). This was also studied in vivo in 8 asthmatic volunteers 
who had histamine bronchial provocation testing in a double-blinded fashion in the 
presence of infusions of placebo (5% dextrose) and angiotensin II (1 and 2 ng/kg/min).
Angiotensin II in subthreshold doses for contraction of airway smooth muscle 
had no effect on histamine-induced bronchoconstriction in the human airway neither in 
vitro nor in vivo.
3. Effect of Angiotensin II on Remodelling of Rat Airway & Vasculature
The effect of endogenous activation of the renin-angiotensin system by dietary 
sodium restriction and subcutaneous infusion of angiotensin II on the rat airways was 
compared to the mesenteric vasculature. DNA synthesis was measured by infusing the 
thymidine analogue bromo-2’-deoxyuridine subcutaneously then revealing those cells 
undergoing DNA synthesis using immunocytochemistry. Changes in the volume of the 
airway tissues were measured morphometrically.
Endogenous activation of the renin-angiotensin system in rats known to increase 
arterial medial DNA synthesis results in increased renin mRNA expression in the renal 
juxta-glomerular cells with increased plasma aldosterone and plasma renin activity and 
minor insignificant variations in blood pressure. However, no change was seen in DNA 
synthesis or morphometry of the airways.
Similarly, infusion of angiotensin II for two weeks in rats causes a rise in blood 
pressure and suppresses renal juxta-glomerular renin mRNA expression with a non­
significant suppression of plasma renin activity. DNA synthesis increased in the 
mesenteric arterial media and there was a non-significant tendency towards the artery 
wall being thicker. No difference was found in DNA synthesis or morphometry of the 
airways.
4. Evidence for a Local Renin-Angiotensin System in the Human Lung
Samples of normal human lung were obtained from thoracotomy specimens and
were examined by immunocytochemistry for renin and ACE, and by in situ 
hybridisation and Northern blotting for renin mRNA, angiotensinogen mRNA, ACE
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mRNA and ATl receptor mRNA. In situ angiotensin II receptor localisation and 
autoradiography were also performed.
In human lung, ACE was identified in vascular endothelium however, no other 
components of the renin-angiotensin system could be found. In control rat lung tissue, 
angiotensin II receptors appeared to be present.
Conclusion
The renin-angiotensin system is activated in some acute asthmatics but the 
mechanism for this remains unclear. It does not correlate with p-agonist administration 
as hypothesised. The deletion allele of the ACE gene polymorphism may be more 
frequent in asthmatics but larger study numbers are required to confirm this. 
Angiotensin II has no effect on histamine-induced bronchoconstriction despite its 
known potentiation of methacholine and endothelin-1. Although angiotensin II has 
mitogenic effects on human airway smooth muscle cells in vitro, it has no effect on 
airway remodelling in the rat but increases arterial smooth muscle cell DNA synthesis. 
Finally, the presence of ACE in pulmonary vascular endothelium has been confirmed 
and angiotensin II receptors may be present in rat lung but no evidence has been found 
of the other components of the renin-angiotensin system in the human lung.
Thus, the renin-angiotensin system has a minor involvement in asthma with 
borderline clinical relevance in some asthmatics, but is not a major contributor to the 
pathophysiology of asthma.
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INTRODUCTION
1.1 Asthma
Asthma is a chronic inflammatory disease of the airways characterised by the 
symptoms of cough, wheeze, dyspnoea and chest tightness. It can be classified as 
intrinsic, where no environmental cause can be identified, and extrinsic, where an 
identifiable environmental inducer is found (1). The physiological manifestation, 
bronchoconstriction, is caused by a number of factors: these include neural and 
chemical stimuli, inhaled bronchial irritants, stress, cold air and exercise.
1.1.1 History o f Asthma
Asthma was first recognised 3,000 years BC in Ancient China with therapeutic 
use of the plant Ma Huang, a source of ephedrine, documented in 1,000 BC. The 
Ancient Egyptian Ebers papyrus refers to respiratory diseases including asthma in 1550 
BC and around 100 AD in Ancient Greece, Aretaeus described asthma as “heaviness of 
the chest, difficulty breathing while walking on a steep road and wheeze” which 
worsened at night and tended to remit. Maimonides in 1190, advised the avoidance of 
humid air, the importance of maintaining an even temperament and avoiding excessive 
exercise and emotions. The importance of allergen avoidance was first noted by 
Cardamo in 1547 who advised the Archbishop of St. Andrews to remove his feather 
bedding (2).
In the seventeenth century, Van Helmont noted the association between 
wheezing and diet, season and dust exposure, Sir John Floyer identified the 
involvement of tobacco smoke and Thomas Willis described the pathology of asthma as 
“pneumonick” with obstruction of the bronchi by mucus and “convulsive” involving 
bronchoconstriction, also proposing the use of anti-spasmodics as a treatment (3).
Early asthma treatment included ipecacuanha, tobacco smoke, exercise, sea 
travel and strong coffee which was thought to help by preventing sleep but probably 
represents the first use of xanthines (2). In the late 1800’s asthma was thought to be 
caused by vasodilatation, hence the use of vasoconstrictor agents such as cocaine, 
adrenaline, sympathomimetics and steroids, leading serendipitously to the discovery of 
modem bronchodilator therapy (4).
The use of steroids stems from early observations that stressful events with 
elevations of cortisol led to improvements in asthma such that physicians prescribed 
frequent cold bathing; an undoubtedly stressful experience! In 1900, Cohen was the 
first to treat asthma with steroids using dried bovine adrenal glands and noted their 
preventive effect but lack of efficacy in acute asthmatic attacks. However, it was many
18
years later before it was appreciated that glucocorticoids were responsible for this effect 
(4).
1.1.2 Epidemiology
Despite improved knowledge of the aetiology and pathophysiology of asthma, it 
remains a disease of increasing prevalence. The lack of a clear, globally accepted 
definition of asthma reflects the heterogeneity of the disease and its manifestations. 
Asthma can arise at any age and it is difficult to define its exact prevalence. In the 
United Kingdom, around 13% of children have a wheezing episode annually (5). A 
study from Tucson, U.S.A. revealed that49% of children aged 0-6 years had wheeze, 
of which 20% were transient episodes. Those with persistent wheeze had a family 
history of asthma, raised IgE, atopy and positive skin prick testing (6). The 
International Study of Asthma and Allergies in Childhood (ISAAC) quotes a worldwide 
prevalence for wheezing in 13-14 year olds varying from 10% in Singapore up to 29% 
in Australia (7).
Persistence of childhood asthma into adulthood varies from 25% (8) to 72% in 
different studies (9). Those most likely to have persistent asthma have a low FEV15 
airway hyperresponsiveness and a personal or family history of atopy (10), while those 
with mild childhood asthma usually outgrow their disease. The increasing prevalence of 
wheezing may be due to increased sensitisation to inhaled allergens (11). Exposure to 
an increased allergen load, tobacco smoke and worsening air pollution have also been 
implicated. This may be compounded by lower rates of breast feeding, lower 
antioxidant intake, increased salt intake and reduced exposure to childhood infections 
(9).
1.1.3 Aetiology
Asthma is part of the atopic triad along with allergic rhinitis and eczema. In 
adults, wheezing is associated with low socio-economic status, smoking and a family 
history of atopic disease (12). A Norwegian twin study showed a relative risk of 
developing asthma as 17.9 for identical twins compared to 2.3 in non-identical twins, 
suggesting that genetic susceptibility accounted for 75% of the risk (13). Other studies 
have shown that traits for bronchial hyper-responsiveness and increased serum total IgE 
levels are co-inherited (14). The inheritance of asthma is probably polygenic (6) and 
environmental influences seem to be more important than genetic factors as supported 
by migrant studies, in-keeping with the increasing prevalence of the disease (9).
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1.1.4 Pathophysiology
In asthma, airways are sensitised by exposure to inhaled allergens. This results 
in inflammation and bronchial hyper-reactivity, the hallmark of asthma. Attacks are 
triggered by exposure to allergens (e.g. house dust mite, cats, dogs, etc.), inhaled 
irritants (e.g. smoke, ozone, particulate air pollution), respiratory infections, exercise, 
stress and cold air. In acute asthma there is bronchoconstriction, microvascular leakage, 
mucosal oedema, vasodilation and mucus hypersecretion.
In atopic individuals there is overproduction of allergen-specific IgE. This binds 
to mast cells, basophils and to a lesser extent platelets, monocytes, eosinophils, 
lymphocytes and macrophages (1). Exposure of antigen to bound IgE causes mast cell 
degranulation with release of histamine, leukotriene C4, prostaglandin D2, interleukin-5, 
tryptase (15), granulocyte-monocyte colony stimulating factor (GM-CSF) and 
interleukin-3 (16) resulting in the bronchoconstriction of the early asthmatic response 
(17).
Eosinophils are key players in asthmatic inflammation and are involved in the 
late asthmatic response. Cytokines released from macrophages, T-lymphocytes, 
activated eosinophils and epithelial cells are responsible for the recruitment of 
eosinophils which adhere to vascular endothelium, then migrate into tissues where they 
are primed (17). Eosinophil degranulation releases basic proteins (including major basic 
protein, eosinophil cationic protein (ECP), eosinophil-derived neurotoxin and 
eosinophil peroxidase) and mediators (including platelet activating factor, leukotriene 
C4, tumour necrosis factor-a, interleukin-5 and GM-CSF). ECP is increased in serum 
and broncho-alveolar lavage fluid in asthmatics (18). This results in increased capillary 
permeability, epithelial shedding and activation of neural reflexes via exposed sensory 
nerve endings (Figure 1).
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Figure 1 The pathological inflammatory processes occurring in the asthmatic
airway.
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Adapted from Mac Cochrane et al. (19)
1.1.5 Humoral Control o f the Airways
1.1.5.1 Histamine
Histamine has many actions in the airway and acts via three types of receptor 
(20). Hj-receptors mediate airway smooth muscle contraction, increased vascular 
permeability, increased cyclic GMP and synthesis of prostaglandin & F2a (21). H2- 
receptors increase airway mucus secretion, increase cyclic AMP and cause 
bronchodilatation in some species. H3-receptors have an inhibitory effect on 
parasympathetic ganglionic neurotransmission, an inhibitory effect on mast cell 
histamine synthesis and may serve to limit unnecessary activation of neural reflexes by 
the physiological basal release of histamine from mast cells (22).
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Asthmatics are 100-fold more sensitive than normals to histamine-induced 
bronchoconstriction and inhaled histamine bronchial provocation testing is used in the 
diagnosis of asthma. In addition to Hj-receptor mediated bronchoconstriction, 
histamine also stimulates irritant receptors and activates vagal afferent nerves eliciting 
vagal reflex bronchoconstriction (22). Histamine and methacholine (an acetylcholine 
analogue) have additive effects on bronchoconstriction and histamine selectively 
increases a 2-adrenergic responses in airway smooth muscle.
1.1.5.2 Endothelin-1
Endothelin-1, a potent vasoconstrictor, is increased in symptomatic asthmatics 
(23) and elevated in both plasma (24) and bronchoalveolar lavage fluid (25) in acute 
asthma. Endothelin-1 is also a potent bronchoconstrictor in vitro (26) and in vivo is 
100-fold more potent than methacholine when inhaled by asthmatics (27). In vitro, 
endothelin-1 is a mitogen for airway smooth muscle in many species (28, 29) including 
humans (30, 31) and potentiates the mitogenic effects of other mediators (31, 32). 
Endothelin-1 is secreted by cultured human bronchial epithelial cells (23) and both type 
ETa and ETB endothelin-1 receptors are present on human airway smooth muscle cells 
in vitro (33) where ETB receptors predominate in a ratio of around 2:1 (31). The ETA 
receptor is thought to mediate growth promotion and the ETB receptor is involved in 
bronchoconstriction (31).
1.1.5.3 Leukotrienes
Leukotrienes are implicated in the pathogenesis of asthma. They are synthesised 
by eosinophils, mast cells, macrophages, monocytes and basophils from arachidonic 
acid by the action of the enzyme 5-lipoxygenase to form LTA4. This is subsequently 
converted to either LTB4 by the action of LTA4 hydrolase, or LTC4 by the action of 
LTC4 synthase. The role of LTB4 in asthma is unclear but it is chemotactic for 
neutrophils and eosinophils. The cysteinyl-leukotrienes (LTC4, LTD4 and LTE4) cause 
bronchoconstriction, mucus secretion from goblet cells and submucous glands, increase 
microvascular permeability, induce airway hyperresponsiveness and attract eosinophils. 
As bronchoconstrictors, they are 100-1000 times more potent than histamine. LTD4 is 
the most potent and LTE4 has the most prolonged activity (34).
Following allergen challenge LTC4, LTD4 and LTE4 levels are elevated in 
broncho-alveolar lavage fluid from asthmatics (35). Elevated urinary LTE4 levels (a 
metabolite of LTD4) are found during acute exacerbations of asthma (36) and in aspirin- 
sensitive asthma (37). Leukotrienes may also play a role in remodelling of the asthmatic 
airway (38).
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The most recent asthma treatments to be licensed are aimed at leukotrienes: these 
are cysteinyl-leukotriene receptor antagonists such as zafirlukast, montelukast and 
pranlukast, and 5-lipoxygenase inhibitors such as zileuton. These agents reduce 
symptoms, have additive effects to p2-agonists, have a steroid-sparing effect and are of 
value in aspirin-sensitive and exercise-induced asthma (34).
1.1.5.4 Catecholamines
Circulating adrenaline may have a role in maintaining basal bronchomotor tone 
by reducing bronchial smooth muscle tone via p2-adrenoceptors and prevents 
acetylcholine release from cholinergic nerves. Its role in acute asthma is unclear as 
circulating levels of adrenaline may or not be elevated (39). Following exercise, 
adrenaline increases causing bronchodilation in both normal and asthmatic volunteers, 
possibly antagonising the bronchoconstrictor effects of exercise in asthma (40). 
Noradrenaline and dopamine have no effect on bronchomotor tone in asthmatics (40).
1.1.5.5 Others
Atrial natriuretic peptide (ANP) causes natriuresis, diuresis, vasodilatation and 
inhibits aldosterone, angiotensin II and endothelin. ANP receptors exist on bronchial 
smooth muscle and ANP causes bronchodilation and protection against histamine- and 
distilled water-induced bronchoconstriction (40). Thyroid hormone excess worsens 
asthma control possibly by downregulating p-adrenoceptor responsiveness, altering 
arachidonic acid metabolism and weakening respiratory muscles (40). Progesterone 
may be beneficial for women with pre-menstrual exacerbations of asthma, but 
otherwise shows no association with pulmonary function. Oestrogen may have a 
steroid-sparing effect in post-menopausal asthma, but hormone replacement therapy has 
also been associated with an increased risk of late-onset asthma (40).
1.1.6 Neural Control o f the Airways
There are three mechanisms of neural control of the airways: adrenergic control 
is mediated by circulating adrenaline released from the adrenal medulla and 
noradrenaline released from adrenergic neurones. In the airways, adrenergic neurones 
are sparse but innervate bronchial blood vessels, submucosal glands and may modulate 
neurotransmission in parasympathetic ganglia. Constriction of airway smooth muscle is 
mediated by a-adrenoceptors but this is not thought to have a major role in asthma. 
Bronchodilatation is mediated by p2-adrenoceptors and it has been suggested that there 
may be a defect in P2-adrenoceptor function in asthmatic airway smooth muscle (1). p2-
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adrenoceptors are also present on cholinergic neurones where they inhibit acetylcholine 
release (22).
Inhibitory non-adrenergic non-cholinergic (i-NANC) nerves cause airway 
smooth muscle relaxation. Nitric oxide is the bronchodilator neurotransmitter and 
antagonises acetylcholine in vitro (41). Excitatory NANC nerves may cause 
bronchoconstriction via the release of substance P (1).
Vagal parasympathetic nerves mediate cholinergic airway control and contribute 
to basal airway tone, bronchoconstriction following stimuli, ciliary movement and 
submucosal gland secretion. Nicotinic receptors mediate cholinergic neurotransmission 
within parasympathetic ganglia and facilitate the release of neuropeptides from sensory 
neurones (22). Muscarinic receptors mediate the majority of cholinergic effects in the 
airway.
Five types of muscarinic receptors have been cloned but the pharmacological 
effects are known for only three. Mg-muscarinic receptors predominate in proximal 
airways and mediate bronchoconstriction. M2-receptors on pre-synaptic cholinergic 
nerve terminals provide negative feedback by inhibiting acetyl choline release. They 
may be defective in asthma. They also inhibit noradrenaline release from adrenergic 
nerves (22) and Mj-receptor function is also inhibited by eosinophil major basic protein 
(41) and influenza virus (22). Mx-receptors have a facilitatory effect on parasympathetic 
ganglia and inhibit noradrenaline release from sympathetic nerves (22).
Cholinergic activity is also inhibited by adrenergic agonists acting on inhibitory 
P2-adrenoceptors on cholinergic nerves and by prostaglandin E .^ However, 
acetylcholine can augment histamine release after allergen challenge and promote 
leukotriene release in vitro (42).
1.1.7 Modulation o f Neurotransmission in the Airways
Bronchoconstriction or bronchodilatation is the end result of a complex 
interaction of many influences on the neurones controlling the airways and also direct 
stimulation of airway smooth muscle. Many facilitatory and inhibitory influences act 
simultaneously, converging on a final common pathway such as an intracellular second 
messenger or an ion channel.
There are many potential sites for modulation of neurotransmission and the 
effects at these sites vary widely between species. In the airway wall, parasympathetic
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ganglia are innervated by sympathetic nerves, sensory nerves and are susceptible to the 
actions of inflammatory mediators. Neurotransmitter release from pre- and post­
ganglionic parasympathetic neurones, noradrenaline release from adrenergic neurones, 
neuropeptide release from C-fibres and modulation of sensory nerves can occur (22). 
The majority of the work in this field has been carried out on many different species in 
vitro and therefore may not be applicable in vivo to human asthmatics.
In parasympathetic ganglia, cholinergic neurotransmission may be inhibited by 
p2-adrenoceptors, facilitated by -muscarinic receptors and inhibited by H3-histamine
receptors (22). However, histamine can facilitate ganglionic neurotransmission in 
guinea pig airways in vitro via acetylcholine release (43). Prejunctional cholinergic 
neurones are inhibited by a 2-adrenoceptors, p2-adrenoceptors, Mj-muscarinic 
receptors, vasoactive-intestinal peptide (VIP), PGE2, nitric oxide and opioids (22), and 
potentiated by angiotensin II (44), thromboxane, substance P, neurokinin A, PGF2a 
and PGD2 (22).
Co-transmitters can affect other neurotransmitters; neuropeptide Y amplifies 
sympathetic neuronal effects and VIP is an inhibitory co-transmitter with acetylcholine. 
Afferent sensory neurones may be sensitised by PGE2, PGI2, arachidonic acid, 
bradykinin, histamine and acetylcholine via nicotinic receptors, and inhibited by opioids 
(22).
The clinical relevance of neuromodulation in asthma remains to be clarified. In 
asthma, many different factors interact simultaneously with inflammatory mediators 
playing an important role, however in vitro studies examine individual factors in 
isolation. Further work on human airway tissue both in vitro and in vivo is required.
1.2. Airway Remodelling In Asthma
1.2.1. Airway Remodelling
Vascular congestion and local fluid exudation in acute inflammation, and 
connective tissue deposition and epithelial metaplasia in chronic inflammation, 
contribute to airway wall thickening (45). In chronic asthma, airway remodelling 
contributes to airflow obstruction by an increase in airway smooth muscle (46), 
increased volume of mucous glands (47), epithelial loss (48) and subepithelial fibrosis 
(49). Thickening of the subepithelial region is due to collagen deposition by 
myofibroblasts (49) beneath the basement membrane (50) and not thickening of the 
basement membrane as previously believed. This may be mediated by transforming
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growth factor-p1 (TGF-p^ which is expressed by bronchial epithelial cells (51). These 
changes may be reversible as airway wall thickening in occupational asthma regresses if 
antigen exposure ceases (52).
Thickening of the airway wall results in greater narrowing of the lumen and 
even occlusion of the airway for a given contraction of smooth muscle (53). Asthmatic 
airways have fewer submucosal folds than normal airways resulting in a reduced load 
on the airway smooth muscle thus allowing greater luminal narrowing for a given 
contraction (54). In addition, exudation of plasma into the airway lumen increases the 
surface tension causing instability (55).
1.2.2 The Functional Role O f Airway Smooth Muscle
In normal human lungs there is relatively more smooth muscle in the peripheral 
than the central airways suggesting a regulatory function for airflow in the former 
region (56). In isolated canine lungs the site of maximal airway narrowing is the 
intermediate airways (57). A computer model of airway narrowing confirms that 
peripheral airways contribute most to airway resistance (58).
It is believed that bronchial smooth muscle is the most important functional 
component of airway wall thickening in asthma and contributes to airway hyper­
responsiveness (53, 59, 60). Early pathological studies of asthmatic lungs found a 3- 
fold increase in bronchial smooth muscle compared with normals. Increased volume 
and muscle fibre number suggests hyperplasia as the main pathogenic mechanism (46, 
61). In fatal asthma there is a general increase in airway wall thickness compared to 
lungs from asthmatics who have died from other causes. This is particularly true in 
smaller bronchi (60) where there is a significant increase in bronchial smooth muscle 
volume (47). Emerging evidence suggests that there are different patterns of airway 
smooth muscle thickening: Type I where hyperplasia occurs only in larger bronchi and 
Type II where hypertrophy occurs throughout the bronchial tree, increasing peripherally 
(62). In isolated canine lungs, smaller airways have greater reactivity to histamine than 
larger airways (63).
However, Bramley and colleagues (64) have shown a similar amount of lobar 
bronchial smooth muscle in asthmatic and normal airways, but a 3-fold increase in 
shortening in the asthmatic airway smooth muscle. Axial sections of 2nd to 4th 
generation large human airways show no evidence of increased airway smooth muscle 
in asthmatics but reveal a substantial component of extracellular matrix and connective 
tissue within the airway smooth muscle (65). Therefore excessive bronchoconstriction
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in asthma is not solely due to excess agonist stimulation but may involve post-junctional 
factors within airway smooth muscle (66) and reduced load by decreased airway 
elasticity. Reduced elasticity may be due to destruction of extracellular matrix by 
proteases released from inflammatory cells (64). In vitro, collagenase treatment of 
human airway smooth muscle allows greater muscle shortening (67). Reduced 
subepithelial elastin may also contribute to decreased elasticity (64).
Adventitial thickening may facilitate uncoupling of the elastic recoil forces from 
surrounding parenchymal lung tissue permitting excessive smooth muscle shortening 
(53, 68). This could explain the discrepancies found between airway smooth muscle 
shortening in vivo and in vitro (69).
1.2.3 Mechanism o f Airway Smooth Muscle Growth
In asthma, the mechanism of airway smooth muscle thickening remains 
controversial. There are similarities to arterial remodelling in cardiovascular disease (70) 
such as hypertrophy of vascular smooth muscle in hypertension. Indeed, physical 
stretching stimulates proliferation of airway smooth muscle cells in vitro (71). 
Furthermore it has been hypothesised that "overwork" of airway smooth muscle cells 
due to hyper-reactivity may result in hypertrophy (62) but there is no evidence to 
support this. Biopsies from human asthmatic bronchi show an association between 
airway smooth muscle proliferation in vivo and inflammatory cell counts from 
bronchoalveolar lavage fluid suggesting a role for inflammatory mediators and 
cytokines (72).
Several growth promoters have now been implicated in airway smooth muscle 
cell proliferation but much of this work has been carried out in vitro and it is not known 
if these results can be extrapolated to airway growth in vivo. Growth of airway smooth 
muscle cells may involve phenotypic modulation from contractile to synthetic 
phenotypes which has been demonstrated in vitro. The synthetic phenotype has greater 
mitogenic activity and may be more excitable (73).
1.2.4 Promoters o f Airway Smooth Muscle Cell Growth
As discussed above, in chronic asthma many inflammatory cytokines, growth 
factors and peptides affect cell growth: these are summarised in Table I. Several of 
these growth promoters have been identified in airway tissues: Platelet-derived growth 
factor (PDGF) is the most important circulating mitogen (74) and occurs in bronchial 
epithelial cells (51) and in interstitial monocytes and macrophages. PDGF p-receptors
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are present on mononuclear interstitial cells, the baso-lateral membrane of epithelial cells 
(75) and have been identified on sheep airway smooth muscle cells in vitro (76).
Endothelin-1 has been found in cultured human asthmatic bronchial epithelial 
cells and the endothelin-1 receptor has been identified on human (23) and sheep airway 
smooth muscle cells with the ETA receptor subtype predominating (29). Circulating 
GM-CSF is elevated in bronchoalveolar lavage fluid from asthmatics (77), is present in 
asthmatic bronchial epithelial cells (78) and can stimulate fibroblast growth in vivo in 
rats (79). Eosinophils can stimulate human fibroblast growth in vitro (80). Interleukin- 
lp  is elevated in asthmatic broncho-alveolar lavage fluid (81) and stimulates guinea pig 
airway smooth muscle cell growth in vitro (82, 83). Both insulin-like growth factor 
(IGF) and TGF~P1 are expressed in bronchial epithelium in normal and asthmatic 
airways (51).
Several growth promoters are known to have synergistic effects on cell growth 
in vitro. Endothelin-1 has synergistic effects with PDGF and epidermal growth factor 
(EGF) in vitro (31, 32, 84). Bradykinin and LTD4 potentiate the effect of EGF on 
human airway smooth muscle cells in vitro (31).
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Table I Promoters o f airway growth.
M itogen Cell Type Experim ent Species R eference
PDGF ASMC In vitro Sheep (76)
Leukotriene D4 ASMC In vivo Rat (59)
Leukotriene D4 ASMC In vitro Human (85)
Endothelin-1 ASMC In vitro Rabbit (86)
Endothelin-1 ASMC In vitro Sheep (29)
Endothelin-1 ASMC In vitro Human (33)
Histamine Fibroblasts In vitro Human (87)
Histamine ASMC In vitro Dog (88)
Tryptase ASMC In vitro Dog (89)
T lymphocytes ASMC In vitro Human (90)
(3 - Hexosami ni dase ASMC In vitro Cow (91)
Interleukin-1(3 ASMC In vitro Guinea pig (83)
EGF ASMC In vitro Guinea pig (92)
EGF ASMC In vitro Cow (93)
EGF ASMC In vitro Human (94)
Thromboxane A2 ASMC In vitro Rabbit (28)
Thrombin ASMC In vitro Human (95)
IGF-1 ASMC In vitro Rabbit (96)
IGF-1 Fibroblasts In vitro Human (97)
TNF-a ASMC In vitro Human (98)
Substance P ASMC In vitro Rabbit (99)
Serotonin ASMC In vitro Dog (100)
Angiotensin II ASMC In vitro Human (101)
Physical stress ASMC In vitro Dog (71)
Hyperoxia ASMC In vivo Rat (102)
Hyperoxic BALF ASMC In vitro Rat (103)
Isocyanates ASMC In vivo Human (52)
Inhaled allergen ASMC In vivo Cat (104)
Abbreviations: PDGF - Platelet-derived growth factor; ASMC - Airway smooth muscle 
cell; EGF - Epidermal growth factor; IGF - Insulin-like growth factor; TNF - Tumour 
necrosis factor; BALF - Bronchoalveolar lavage fluid
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Only a very limited number of studies have used in vivo models to assess cell 
growth within the airways. In sensitised cats, repeated allergen challenge causes 
histological changes similar to those found in human asthmatics with increased airway 
smooth muscle (104). Similar experiments in rats result in increased airway smooth 
muscle and bronchial responsiveness which correlates in the larger airways only (59). 
Occupational exposure to inhaled isocyanates results in structural changes in the airway 
wall which are reversible upon avoidance of further antigen exposure (52).
Exposure of rat airways to hyperoxia (Fi02 >95%) results in an increase in the 
epithelial and airway smooth muscle cells with a significant increase in DNA synthesis 
and bronchial hyper-responsiveness (102). Bronchoalveolar lavage fluid obtained from 
hyperoxic rat airways also stimulates rat airway smooth muscle cell growth in vitro 
(103).
1.2.5 Inhibitors O f Airway Smooth Muscle Growth
Several inhibitors of airway smooth muscle cell growth are listed in Table II.
Table II Inhibitors o f airway smooth muscle growth.
Growth inh ib ito rs Cell type Experim ent Species Reference
Isoprenaline ASMC In vitro Human (105)
Salbutamol ASMC In vitro Human (30)
Heparin ASMC In vitro Cow (106)
Heparan sulphate ASMC In vitro Cow (106)
Fragmin ASMC In vitro Cow (106)
Nedocromil sodium ASMC In vitro Rat (107)
LTD4 antagonist 
(MK-571)
ASMC In vitro Rat (38)
VIP ASMC In vitro Human (108)
TGF-pj ASMC In vitro Human (109)
Abbreviations: ASMC - Airway smooth muscle cell; LTD - Leukotriene D; VIP - 
Vasoactive intestinal peptide; TGF - Transforming growth factor.
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1.3 The Renin-A ngiotensin System
The renin-angiotensin system is primarily involved in sodium and water 
homeostasis but also has an important role in cardiovascular disease. Angiotensin II, 
the active octapeptide hormone is the end result of a cascade shown in Figure 2 
beginning with angiotensinogen.
Figure 2 The renin-angiotensin system cascade.
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Angiotensinogen is synthesised primarily in the liver and circulates in plasma. 
Its production increases in response to angiotensin II (110), acute inflammation (111), 
glucocorticoids, haemodilution, oestrogens and hypoxia (112). Angiotensinogen is 
cleaved by renin to angiotensin I which is in turn converted by angiotensin-converting 
enzyme (ACE) to angiotensin II, which is subsequently degraded by angiotensinases to 
angiotensin III and inactive peptide fragments (Figure 2).
Direct cleavage of angiotensinogen to form angiotensin II can also be achieved 
by the action of the enzymes human neutrophil cathepsin G (113), tonin (114), trypsin 
(115), kallikrein, elastase and tissue plasminogen activator. In addition, cathepsin G, 
cathepsin D (116) pepsin (117), chymase (118, 119) and aspartyl proteases can convert 
angiotensinogen to angiotensin I. Conversion of angiotensin I to angiotensin II is also 
mediated by cathepsin G and mast cell chymase (120). An alternative ACE-independent 
pathway for the formation of angiotensin II occurs during exercise (121).
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Renin is a peptidase, first identified 100 years ago. Its release is increased by 
renovascular receptors responding to alterations in renal perfusion pressure, macula 
densa renal tubule receptors responding to alterations in sodium, stimulation of renal a -  
and p-adrenoceptors, neurohypophyseal hormones, catecholamines and 
cardiopulmonary receptors. Renin release is suppressed by atrial natriuretic factor, 
adenosine, angiotensin II and vasopressin. Renin is predominantly synthesised in the 
juxta-glomerular cells in the kidneys then stored until required (122). Many other 
tissues are a source of renin including the brain (123), arteries, veins, heart (124), 
adrenal glands (125), submandibular glands (126), testes (127), ovaries (128) and 
uterus (129).
Circulating angiotensin II is formed mainly in the pulmonary capillaries where 
up to 80% of ACE conversion occurs due to the high concentration of endothelial cells 
(130). Angiotensin II acts on the adrenal gland to release aldosterone but also has many 
other actions: It is a potent vasopressor, stimulates growth of vascular smooth muscle 
and other tissues (see Section 1.5), acts on the liver to stimulate glycogenolysis, 
gluconeogenesis and angiotensinogen synthesis, stimulates prostaglandin formation in 
the rat renal medulla and acts as a neurotransmitter in the brain to increase blood 
pressure, stimulate drinking, increase salt appetite and to release pituitary hormones 
including adreno-corticotrophic hormone, oxytocin and luteinising hormone (131). 
Angiotensin II is also a weak bronchoconstrictor (132) and induces endothelin-1 
secretion (133). The renin-angiotensin system is also stimulated by physical exercise 
(121, 134), especially in the presence of hypoxia (135).
Angiotensin II receptors are coupled to G proteins and are found in vascular 
smooth muscle, adrenal cortex and medulla, kidney, myocardium, liver, brain, 
pituitary, hypothalamus, platelets, monocytes, macrophages (131), uterus, gut, gonads 
and lung (136, 137). There are three angiotensin II receptor subtypes with the type 1 
receptor (ATJ predominating. These are further subdivided into AT1a and AT1B which 
mediate most known actions of angiotensin II. The type 2 receptor (AT2) mediates an 
inhibitory effect of angiotensin II on cell proliferation in some tissues (138) and may be 
involved in fetal growth (139). The function of the type 3 (AT3) receptor is not known. 
It has extra sites for protein kinase C phosphorylation and may be involved in the 
differential regulation of angiotensin II receptors in response to variations in dietary 
sodium (140).
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1.4 The Renin-A ngiotensin System In Asthma
The renin-angiotensin system is activated in acute severe asthma although not in 
stable asthmatics (40, 132). The reason for this and the mechanisms involved are 
unclear.
When infused intravenously, angiotensin II causes bronchoconstriction in mild 
asthmatics (132). In vitro it constricts human (141) and bovine bronchial rings (26). 
Angiotensin II potentiates the bronchoconstrictor effects of methacholine on human 
airway in vivo and in vitro (141) and endothelin-1 on bovine airway in vitro (26). It 
also potentiates vagally mediated contraction of rabbit airway smooth muscle via a pre­
junctional effect on cholinergic nerve terminals (44).
Inhaled and intravenous salbutamol raise plasma angiotensin II levels by an 
ACE-dependent mechanism (142, 143). Plasma levels of salbutamol in acute severe 
asthma vary widely (144), however plasma levels of angiotensin II induced by 
salbutamol experimentally do not attain the values seen in acute severe asthma, therefore 
additional mechanisms seem to be involved. Catecholamine release, hypoxia, electrolyte 
imbalance, hypotension, vasodilatation and the influence of other circulating mediators 
may have a role. Angiotensin II could also be formed by tissue chymases and 
inflammatory proteases in acute asthma.
Recent work has shown that angiotensin II induces human airway smooth 
muscle cell proliferation and hypertrophy in vitro (101). Therefore it is possible that 
angiotensin II has a role in airway remodelling.
1.5 The Role Of The Renin-Angiotensin System In Remodelling
The renin-angiotensin-aldosterone system is one of the most important growth 
promoters. Angiotensin II stimulates growth of fibroblasts, bovine adrenocortical cells 
(145), cardiac myocytes, renal tubular cells (146) and can increase collagen and 
fibronectin synthesis by vascular smooth muscle cells in vitro (147). Angiotensin II is 
mitogenic for vascular smooth muscle in vitro causing hyperplasia and hypertrophy 
(148) mediated by the ATL subtype of angiotensin II receptor (149). In vivo angiotensin 
II increases vascular smooth muscle cell proliferation both in normal arteries (150) and 
following intimal injury in rats (151).
The vascular myointimal hyperplasia in response to angiotensin II in vivo may 
be mediated by induction of both PDGF (which has proliferative effects) and also TGF- 
Pj (which has anti-proliferative effects)(109), with a resultant net hypertrophic effect.
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Vascular endothelium releases prostacyclin and nitric oxide which antagonise these 
actions, but endothelial injury may permit angiotensin II to cause vascular smooth 
muscle cell proliferation (152). A similar situation could operate in the airways as 
airway epithelium expresses TGF-pj mRNA (51, 153) and epithelial shedding is a 
recognised feature of asthma (48).
Angiotensin II has also been implicated in cardiac remodelling following 
myocardial infarction, in left ventricular hypertrophy and in arterial medial thickening in 
hypertension. In the arterial wall the effect of angiotensin II on vascular smooth muscle 
cells is independent of blood pressure (154) and is increased following intimal injury. 
ACE inhibitors and angiotensin II receptor antagonists inhibit angiotensin II-mediated 
vascular smooth muscle cell proliferation in vivo and in vitro (149, 155) and can inhibit 
cardiac muscle hypertrophy in hypertensive rats (145).
1.6 Evidence For A Local Renin-A ngiotensin System In The L ungs
Most tissues that respond to the circulating renin-angiotensin system also have 
the capacity to synthesise its components. Local renin-angiotensin systems are 
established in the kidney (124), brain (123), heart, vasculature (124), adrenal glands 
(125), salivary glands (126), testes (127), ovary (128) and uterus (129, 156). The 
actions of circulating angiotensin II in asthma causing airways constriction (132) and 
pulmonary vasoconstriction (157) suggest that the lungs may have a local renin- 
angiotensin system.
It is well known that the pulmonary capillaries are rich in ACE (158, 159). 
Renin has been identified in human lung vasculature around a variety of pulmonary 
tumours (160), in an anaplastic pulmonary adenocarcinoma (161), in an oat cell 
bronchial carcinoma (162) and in a pulmonary metastasis from an epithelioid sarcoma 
(163). Renin mRNA has also been isolated from rat lung (164).
Angiotensinogen mRNA (165) and AT2 receptor mRNA have been isolated 
from rat lung (139). AT! angiotensin II receptor mRNA has been extracted from human 
lung (137), adult rat (166) and fetal rat lung (167). ATX receptors have been localised 
immunohistochemically to bronchial muscle in rat lungs (136). The AT1a receptor 
subtype accounts for 85% of the angiotensin II receptor mRNA expressed (168). A 
third type of angiotensin II receptor (AT3) has also been demonstrated in rat lung (140).
However, like other local renin-angiotensin systems, a local pulmonary system 
would be unlikely to make a significant contribution to circulating levels of renin and
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angiotensin II; however, it could influence airway bronchoconstriction and remodelling 
at a tissue level.
1.7 The ACE Gene Insertion/D eletion Polym orphism
Angiotensin-converting enzyme is a zinc metallo-peptidase which cleaves the 
dipeptide His-Leu from angiotensin I and is responsible for the generation of the 
majority of angiotensin II. It also inactivates bradykinin and substance P. Most ACE is 
found in the lungs and is membrane-bound on endothelial, epithelial and neuro­
epithelial cells (169). It is also found in T-lymphocytes (170) and free in plasma, 
amnioticand seminal fluids (169).
There is a wide variation in serum ACE activity within the general population 
and around 50% of this can be attributed to a variation in genotype (169). A 
polymorphism of the ACE gene involving the insertion or deletion of a 287 base-pair 
repeat sequence within intron 16 has been identified (171). The deletion homozygote 
(DD)has twice the ACE activity of the insertion homozygote (II) with the heterozygote 
(ID) intermediate (169). Ueda et al. (172) confirmed this finding demonstrating higher 
ACE activity in vivo for the DD genotype, with a greater rise in blood pressure 
following infusion of angiotensin I. It is also suggested that this polymorphism could 
affect individual responsiveness to ACE inhibitors.
There is now an extensive literature examining the association of the ACE gene 
polymorphism with predominantly cardiovascular disease. The ACE DD genotype is 
associated with idiopathic and ischaemic dilated cardiomyopathy (173), fatal myocardial 
infarction and sudden cardiac death (174), left ventricular hypertrophy (with the 
strongest association in normotensive subjects) (175), diabetes, sudden cardiac death 
from hypertrophic obstructive cardiomyopathy (176) and coronary arterial disease but 
not angiographic coronary arterial stenosis (177). Cardiac tissue ACE activity is highest 
in those with the DD genotype in non-cardiac deaths (178).
A meta-analysis of ACE genotype and myocardial infarction confirms that the 
DD homozygote confers an increased risk with an odds ratio of 1.26. However, the 
clinical importance of this as an independent risk factor is unclear with the authors 
pointing out that many of the studies are retrospective resulting in a survival bias (179), 
although the risk appears highest in those with few other conventional risk factors 
(180).
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An association has been demonstrated between the DD genotype and common 
carotid artery intimal and medial thickness although the difference is small (12%) and 
unlikely to be of clinical significance as no difference was found in the internal carotid 
arteries or in plaque formation (181).
Although an association has been shown in the above instances this does not 
prove causality and the mechanisms involved remain to be clarified. There may yet be 
hitherto unidentified mutations of the ACE gene within the 10,000-100,000 base pair 
range which could be involved in the variation in ACE activity (177).
Other polymorphisms of the renin-angiotensin system have been identified 
including that of the ATj angiotensin II receptor which has a small association with 
hypertension (182) and the angiotensinogen gene T235 variant which is associated with 
an increased risk of hypertension, coronary heart disease and myocardial infarction 
independent of ACE genotype (183). The possibility of synergistic increased risk of 
myocardial infarction between ACE DD genotype and a variant of the ATX receptor gene 
has also been suggested (184).
The ACE gene polymorphism may thus partly explain the variation in levels of 
angiotensin II found in asthma.
1.8 Salt And Asthm a
The association between salt intake and asthma is an area of controversy. A high 
salt intake may be associated with an increase in wheezing and increased bronchial 
hyper-responsiveness. This is related to the sodium rather than the chloride component 
and the association is stronger in men than in women. One explanation may be the 
reduction in circulating catecholamines which occurs with salt loading (185).
The renin-angiotensin system is involved in salt and water homeostasis and is 
activated by a low salt intake. This would increase angiotensin II which is known to 
have an effect on asthmatic airways (132), upregulate adrenal zona glomerulosa 
angiotensin II receptors but downregulate vascular smooth muscle cell receptors (131). 
Indeed rats on a low sodium diet have increased plasma renin activity and increased 
vascular DNA synthesis in the media of the mesenteric arteries (186).
Conversely, if a high salt intake is associated with asthmatic symptoms and 
causes lower angiotensin II levels due to negative feedback, it would appear at first 
glance that the bronchoconstrictor effects of angiotensin II may not be of primary
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importance in the salt and asthma equation. However, since a high salt intake 
upregulates vascular smooth muscle cell angiotensin II receptor density it may also do 
the same for airway smooth muscle cells, thereby increasing the sensitivity to 
angiotensin II.
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HYPOTHESES
2.1 H ypotheses
Asthma is a complex disease, the clinical manifestations of which are the net 
result of the interaction of many different mediators and cytokines involving multiple 
cell types and tissues. The renin-angiotensin system appears to play a part within this 
complicated milieu but its precise role is unclear. Figure 3 represents the schematic 
relationship between asthma and the renin-angiotensin system postulated by the work of 
this thesis.
F igure 3 The proposed relationship between the renin-angiotensin system and
asthma.
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The hypotheses to be tested in the work of this thesis are as follows:
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2.1.1 Activation of the renin-angiotensin system in acute severe asthma may be due 
primarily to the large amounts of p2-agonist medication administered during attacks. 
However, many different factors are altered during acute attacks of asthma which may 
also play a role in activating the renin-angiotensin system, possibly by synergistic 
mechanisms. These include endogenous catecholamines, hypoxia, hypotension, 
inflammatory mediators, proteases and cytokines, which will also be measured and 
correlated.
2.1.2 Angiotensin II which is known to have a putative effect on the 
bronchoconstrictors methacholine and endothelin-1 may also potentiate the effects of 
histamine, another clinically important bronchoconstrictor, in the human airway both in 
vitro and in vivo.
2.1.3 Given that most organs which respond to the renin-angiotensin system also 
appear to have local tissue systems, it would seem logical to suggest that the lungs also 
have a local renin-angiotensin system. This would necessitate the presence of 
angiotensinogen, renin, ACE and angiotensin II receptors within lung tissue.
2.1.4 Angiotensin II is a growth promoter for airway smooth muscle in vitro and thus 
may cause remodelling of the rat airway in vivo by subcutaneous infusion and by 
endogenous activation of the renin-angiotensin system by dietary sodium depletion.
2.1.5 The homozygote deletion genotype of the ACE gene insertion/deletion 
polymorphism is associated with higher plasma levels of angiotensin II and thus may be 
more prevalent in asthmatics, particularly those with activation of the renin-angiotensin 
system.
2 .2  Aims of the T hesis
The work of this thesis aims to define the pathological or physiological purpose 
which activation of the renin-angiotensin system serves in asthma. If this is a clinically 
important pathological role either by causing bronchoconstriction directly or potentiating 
the effect of other bronchoconstrictors, or by increasing airway smooth muscle growth 
then potential intervention with ACE inhibitors or, better still, angiotensin II receptor 
antagonists may be beneficial. This would require further study and clarification but 
could be of clinical relevance in the treatment of asthma.
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3. THE MECHANISM OF ACTIVATION 
OF THE RENIN-ANGIOTENSIN SYSTEM 
IN ACUTE SEVERE ASTHMA
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3.1 In troduction
The renin-angiotensin system is activated in some cases of acute severe asthma 
(40, 132). The mechanism is unclear, but recent evidence has shown that plasma renin 
and angiotensin II levels rise in response to nebulised and intravenous salbutamol (142, 
143). There is wide variation in plasma p2-agonist levels in acute asthma (144) and this 
could account for the variation found in renin and angiotensin II levels.
However, the degree of activation of the renin-angiotensin system following 
administration of p2-agonists is less than that seen in acute asthma, suggesting the 
involvement of additional mechanisms. The generation of angiotensin II via an 
“alternative” pathway through the action of inflammatory proteases (113) either 
circulating or within the airways could augment the “classical” activation of the renin- 
angiotensin system. Endogenous catecholamines released during an acute attack of 
asthma (39) could also stimulate p-adrenoceptors on juxta-glomerular cells in the 
kidney (187) resulting in renin release. These may act synergistically with systemically 
absorbed salbutamol. Variations in serum ACE activity could also contribute to the wide 
range of plasma angiotensin II levels found in acute asthma.
This study aims to clarify the role of plasma levels of circulating P2-agonists in 
activation of the renin-angiotensin system in acute severe asthma and to define the 
contribution of other factors and explore the possibility of a synergistic effect as 
suggested above. Since it has been established that angiotensin II levels are elevated in 
acute severe asthma (132), no control group has been examined.
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3.2 M ethods
3.2.1 Study Subjects
A non-consecutive series of forty adult asthmatic patients (26 female) with mean 
(standard deviation) age 44.8 (17.1) years were recruited into the study. All presented 
non-consecutively at the accident and emergency department with acute exacerbations of 
asthma unresponsive to their regular medication and requiring hospital admission for 
treatment. Admission parameters are shown in Table III. Spirometry was not measured 
during the acute admission but pre-morbid values were available for 19 of the 40 study 
subjects. Due to the acute nature of the admissions 12 of the 40 patients were already 
receiving supplementary inspired oxygen at concentrations varying from 24-100% by 
the time arterial blood gases were measured. The values for Pa02 therefore over­
estimate the true Pa02 on breathing air alone.
Table III  Study patient characteristics on hospital admission.
Mean S tandard  Deviation
Age 44.8 (17.1)
Peak Expiratory Row Rate 
(% Predicted)
35.2 (18.3)
FEVj (% Predicted) [n=19] 52.1 (28.4)
Pulse Rate 108.1 (16.4)
Oxygen Saturation (%) * 94.0 (3.7)
Pa02 (kPa) * 11.3 (4.6)
PaC02 (kPa) 4.9 (1.4)
Systolic BP (mmHg) 139.5 (22.8)
Diastolic BP (mmHg) 86.0 (16.0)
Sex Ratio (M:F) 14: 26
Smokers 21
n = 40 unless otherwise stated in the text.
* Denotes values obtained when patients receiving supplementary oxygen.
FEVj - Forced Expiratory Volume in One Second; BP - Blood Pressure.
All patients were treated with nebulised salbutamol. Thirty-one also received 
oral prednisolone (dose range 15-40 mg), thirteen received intravenous hydrocortisone, 
one received intravenous salbutamol and one intravenous aminophylline. Thirty-three 
patients were taking regular inhaled corticosteroids, eleven were previously taking oral
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prednisolone, seven oral theophylline, nine inhaled salmeterol and one was on no 
medication. Thirty-nine used inhaled p2-agonists as required (nine via a home 
nebuliser), seven inhaled ipratropium bromide, one inhaled sodium cromoglycate and 
one was on oral P2-agonists. Only two were on regular diuretic treatment and none 
were on angiotensin-converting enzyme inhibitors.
Ethical approval for the study was obtained from the Glasgow West Ethical 
Committee and written, informed consent was obtained from the study volunteers prior 
to entering the study (Appendix 1).
3.2.2 Sample Collection
All patients had blood samples measured within 24 hours of admission (mean 
(SD) time post-admission 13.5 (9.6) hours) for estimation of plasma renin and 
angiotensin II, plasma salbutamol, serum angiotensin-converting enzyme activity, 
adrenaline, noradrenaline, histamine, eosinophilic-cationic protein, endothelin-1, IgE, 
sodium, potassium, urea and creatinine. Plasma salbutamol levels were measured 3.4 
(1.9) hours following the previous dose of salbutamol and the cumulative dose of 
salbutamol administered in the previous 24 hours was estimated. All samples were 
immediately placed on ice until separated by centrifugation at 4°C for 15 minutes at 
3,000 g, then plasma or serum were removed and kept frozen at -20°C until analysis.
3.2.3 Plasma Assays
3.2.3.1 Renin: Plasma renin concentration was measured by an antibody trapping 
technique (188). The intra-assay coefficient of variation is 5.5% and inter-assay 
variation is 11%. The normal reference range for our laboratory is 9-50 pU/ml.
3.2.3.2 Angiotensin II: The assay is a modified radioimmunoassay which uses C18 
cartridges (Sep-Pak; Waters, Milford, MA, USA) to extract angiotensin II from plasma 
(189). The intra-assay coefficient of variation is 6.4% and inter-assay variation 10%. 
The normal reference range for our laboratory is 3-12 pg/ml.
3.2.3.3 Catecholamines: The assays for adrenaline and noradrenaline use a liquid 
chromatography technique with electrochemical detection (190). Both the intra- and 
inter-assay coefficients of variation are below 10%. The reference ranges for our 
laboratory are up to 0.4 nmol/L for adrenaline and up to 5.0 nmol/L for noradrenaline.
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3.2.3.4 Endothelin-1: This is measured by radioimmunoassay using a commercially 
available kit (Nichols Institute, Saffron Walden, UK). The intra-assay coefficient of 
variation is 4.5% and the inter-assay variation 6.8%. The normal reference range for 
our laboratory is 1.6-4.9 pg/ml.
3.2.3.5 Salbutamol: This is a high performance liquid chromatography with solid phase 
extraction using a mobile phase of 39.4% methanol, 59.1% acetonitrile and 1.5% 
ammonium acetate (191). Salbutamol is extracted from plasma using Bond-Elite silica 
cartridges (Jones Chromatography Ltd., Mid Glamorgan, UK) then high performance 
liquid chromatography (10cm Scherisorb S3W-Silica, Hichrom, Berkshire, UK) is 
performed and the drug detected in the effluent by an LS-1 Fluorescence Detector 
(Perkin-Elmer, Beaconsfield, UK). The intra-assay coefficient of variation is 3.9% and 
the inter-assay variation is 4.1 %.
3.2.3.6 Angiotensin-Converting Enzyme Activity: Serum ACE activity is determined by 
a continuous monitoring spectrophotometric method based on the hydrolysis of N-(3- 
(2-furyl)-acrylyl)-L-phenylalanyl-glycyl-glycine (192). The intra-assay coefficient of 
variation is 1.7-6.3% and the inter-assay variation is 3.7-9.7%. The normal range for 
our laboratory is below 88 Units/L.
3.2.3.7 Histamine: This is a radioimmunoassay using a commercial kit (Immunotech 
S.A., Marseille, France) with high-affinity monoclonal antibodies to histamine 
following acylation. The sensitivity of the assay is 0.2 nM. The intra-assay coefficient 
of variation is 3.4-8.9% and the inter-assay variation is 6.4-13.0%. The normal range 
is < 10 nM.
3.3.3.8 Eosinophilic Cationic Protein: This is a double antibody radioimmunoassay 
using a commercially available kit (Pharmacia U.K. Ltd. Milton Keynes, U.K.). The 
sensitivity of the assay is <2(ig/l. The intra-assay coefficient of variation is 4.8-10.9%. 
The normal range for the assay is <20pg/l.
3.2.3.9 Immunoglobulin E: Total serum IgE was measured with a Phadebas RAST kit 
(Pharmacia, U.K.) according to the manufacturer’s recommendations. An estimate of 
error was made at 20% based on the coefficient of variation of the measurements of the 
same internal quality control samples over 50 consecutive weeks. The normal range for 
our laboratory is <120 International kiloUnits/1.
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3.2.3.10 Electrolytes: The sodium and potassium assays use standard ion selective 
electrodes. The normal range for our laboratory is 135-144 mmol/1 for sodium and 3.5-
5.1 mmol/1 for potassium.
3.2.3.11 Renal Function: The assay for urea uses a standard urease method. The 
normal range for our laboratory is 2.5-1.5 mmol/1. The assay for creatinine uses the 
Jasse method measuring in infra-red. The normal range for our laboratory is 60-110 
p. mol/1.
3.2.4 Statistical Analysis
Spearman’s Rank Correlation Coefficient was used to analyse correlations between the 
variables and, as multiple tests were performed, p<0.001 was considered significant.
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3.3 R esults
Although the levels of renin and angiotensin II were not elevated in the study 
group as a whole, a sub-population of asthmatics had raised levels of renin and 
angiotensin II above the normal range for our laboratory, suggesting activation of the 
renin-angiotensin system in these patients (Figure 4). Nineteen (47.5%) of the patients 
had elevated angiotensin II levels and ten (25%) had elevated plasma renin. There was a 
strong correlation between renin and angiotensin II levels (Spearman’s rank correlation 
coefficient ‘p ’=0.942; p < 0.001).
Figure 4 Plot o f plasma renin and angiotensin II levels.
100
M
10 12
Plasma Angiotensin II (pg/ml)
Dotted lines indicate the upper limit of the normal range for plasma renin and 
angiotensin II in our laboratory.
The results of the other assays measured are shown in Figure 5 and listed fully 
in Table IV.
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Adrenaline and noradrenaline correlated strongly with each other (p =0.794; p < 
0.001), although all except one patient had adrenaline levels within the normal range. 
Noradrenaline levels were elevated in only three of the forty asthmatics. Histamine was 
associated positively with eosinophilic cationic protein (p =0.412; p = 0.008) and 
negatively with oxygen saturation (p = - 0.473; p = 0.002), but these values were just 
outwith our limit of statistical significance. Sixteen patients (40%) had raised plasma 
endothelin-1 levels which correlated negatively with peak expiratory flow rate 
(p = -0.37; p = 0.02) but did not reach statistical significance.
The measured plasma salbutamol level related to the estimated dose of 
salbutamol administered in the previous 24 hours but did not attain statistical 
significance (p =0.327; p = 0.045).
Table IV Measurements o f serum and plasma levels made during acute severe
asthma.
M edian In ter-quartile
range
Norm al
range
Angiotensin II (pg/ml) 10.9 (4.3-23.5) [3-12]
Renin (pU/ml) 22.0 (10.0-50.0) [9-50]
Adrenaline (nmol/1) 0.1 (0.10-0.14) [<0.4]
Noradrenaline (nmol/1) 1.3 (0.6-2.2) [<5.0]
Endothelin-1 (pg/ml) 4.9 (3.2-6.4) [1.6-4.9]
Salbutamol (ng/ml) 5.2 (3.0-6.4)
ACE Activity (U/ml) 30.0 (20.5-36.5) [<88]
Histamine (nM) 3.0 (2.0-7.8) [<10]
Eosinophilic Cationic Protein (fig/1) 11.0 (6.0-21.5) [<20]
Immunoglobulin E (kU/1) 182.0 (61.1-744.0) [<120]
Urea (mmol/1) * 4.9(mean) (1.6) [SD] [2.5-7.5]
Creatinine (p mol/1)* 84.9(mean) (25.6) [SD] [60-110]
Sodium (mmol/1)* 138.2(mean) (3.5) [SD] [135-144]
Potassium (mmol/1)* 4.1 (mean) (0.4) [SD] [3.5-5.1]
The results are expressed as median (inter-quartile range) except for those marked (*) 
which are expressed as mean (standard deviation).
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There was no association between plasma renin or angiotensin II levels and 
plasma levels of salbutamol, adrenaline, noradrenaline, endothelin-1, serum total IgE, 
histamine, eosinophilic cationic protein, serum ACE activity, renal function (urea, 
creatinine) or electrolytes (sodium, potassium), any measures of the clinical severity of 
the asthma attack (oxygen saturation, peak expiratory flow rate) or the cumulative doses 
of salbutamol or corticosteroids administered (Table V).
Table V Spearman’s rank correlation coefficients between renin, angiotensin II
and the parameters measured.
Renin Angiotensin II
Renin 0.94*
Angiotensin II 0.94*
Plasma Salbutamol 0.26 0.11
Adrenaline 0.29 0.35
Noradrenaline 0.17 0.22
Histamine -0.02 - 0.07
Endothelin-1 0.13 0.09
Serum ACE Activity -0.10 0.03
Eosinophilic Cationic Protein 0.11 0.10
Immunoglobulin E 0.15 0.16
Urea -0.10 -0.08
Creatinine 0.23 0.26
Sodium -0.07 - 0.04
Potassium -0.01 -0.03
Peak Expiratory How Rate 0.11 0.20
Oxygen Saturation 0.33 0.40
Age - 0.24 -0.20
* Denotes significant correlation (p < 0.001).
Mean (SD) blood pressure was 139.5 (22.8) mmHg systolic and 86.0 (16.0) 
mmHg diastolic. There was no difference in blood pressure between those with 
elevated plasma renin (mean [SD] 135 [16.5] mmHg systolic, 81.1 [15.1] mmHg 
diastolic) and those with normal levels (140.9 [24.4] mmHg systolic, 87.5 [16.2] 
mmHg diastolic) or in those with elevated plasma angiotensin II (135.5 [15.4] mmHg
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systolic, 82.6 [12.7] mmHg diastolic) and those with normal levels (143.0 [27.4] 
mmHg systolic, 89.0 [18.2] mmHg diastolic). There was no correlation between 
systolic or diastolic blood pressure measurements and either renin or angiotensin II 
levels.
3.4 C onclusion
Therefore, although plasma renin and angiotensin II levels are once again found 
to be elevated in a sub-group of asthmatics during acute attacks, no association has been 
found with any of the clinical or the circulating parameters measured.
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THE ACE GENE INSERTION/DELETION 
POLYMORPHISM IN ASTHMA
4.1 In troduction
An insertion/deletion polymorphism of the 16th intron of the angiotensin- 
converting enzyme gene has been identified in the general population (171). This may 
be an independent risk factor in cardiovascular disease with a deletion homozygote 
genotype being least desirable (180). The deletion homozygote of the polymorphism is 
associated with higher serum ACE activity (169) and the propensity to produce higher 
levels of angiotensin II (172). This polymorphism accounts for half of the variation in 
serum ACE activity found in the general population. The results in Chapter 3 again 
show a wide variation in plasma renin, plasma angiotensin II and serum ACE activity in 
acute asthmatic subjects. This study examines the hypothesis that the ACE gene 
polymorphism has a role in the variation in plasma angiotensin II levels found in acute 
asthmatics.
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4.2 M aterials And M ethods
Forty adult asthmatic subjects (26 female), mean (standard deviation) age 44.8 
(17.1) years, with acute exacerbations of asthma requiring hospital admission were 
recruited for the study as previously described and characterised in chapter 3. One 
sample for ACE genotype was damaged leaving n=39. For comparison, serum ACE 
activity and ACE genotype were also measured in a control group of 78 healthy 
volunteers from the West of Scotland, the same geographical area as the asthmatic 
subjects. Of the 78 control volunteers, 47 were female with a group mean (standard 
deviation) age of 35.6 (11.0) years.
A further twenty non-asthmatic subjects (10 female) with mean (standard 
deviation) age 57.2 (17.9) years, were also recruited after hospital admission for acute 
medical emergencies. These included chest pain/angina (n=8), deep venous thrombosis 
(n=2), arrhythmia/palpitations (n=2), pulmonary thrombo-embolism (n=2), syncope 
(n=l), headache (n=l), diabetes mellitus (n=l), vomiting (n=l), back pain (n=l) and 
urinary tract infection (n=l). None were taking ACE inhibitors but six were taking 
beta-blockers, three were taking calcium-channel antagonists and one was taking a 
diuretic. Nineteen were normotensive with one having a blood pressure of 180/100 
mmHg.
Blood samples were obtained in a plain glass tube for serum ACE activity and 
in an EDTA tube for ACE genotype. Serum ACE activity was measured by a 
continuous monitoring spectrophotometric method as previously described in Chapter 3 
(192). ACE genotype was determined by both a 2-primer method of polymerase chain 
reaction according to Rigat et d . (193) and a 3-primer method according to Evans et d. 
(174) (Appendix 2). These two methods were used to ensure that no error occurred 
during the genotyping procedure. Assays for ACE activity and ACE genotyping were 
kindly performed by Dr. Richard Spooner and Dr. Caroline Jagger in the Department of 
Clinical Biochemistry, Gartnavel General Hospital, Glasgow, using techniques which 
they have established in the Department.
Statistical analysis of the results was performed using one-way analysis of 
variance to assess the relationship between ACE genotype and both serum ACE activity 
and plasma angiotensin II, and the age distribution among the ACE genotype sub­
groups. A chi-squared test was used to compare the ACE gene allele frequencies. 
Comparison of ACE activity for each genotype between groups was by the Mann- 
Whitney U-test.
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4.3 R esu lts
The ACE genotypes derived for each individual were in agreement when 
determined by both the 2-primer and the 3-primer methods of analysis. In the asthmatic 
subjects, the deletion homozygote (DD) for the ACE gene was associated with a 
significantly higher (p=0.009) serum ACE activity (median [range] 39.5 [23-62] U/L) 
than the heterozygote (ID) (24.5 [13-72] U/L) and the insertion homozygote (II) (18.5 
[17-20] U/L). This was also the case in the control group, with a significantly higher 
(p=0.007) serum ACE activity (34 [20-47] U/L) in those with the DD genotype than 
those with the ID genotype (27 [12-48] U/L) and the II genotype (20 [10-43] U/L) 
(Figure 6).
F igure 6 Serum ACE activity from acute asthmatics and controls plotted against
ACE genotype.
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Open circles represent acute asthmatics and black circles represent controls.
Bars indicate median values.
There was an increased frequency of the deletion allele in the asthmatic group 
(61.5%) compared to the control group (50.6%) although this did not reach statistical 
significance. In addition, the DD homozygote is present in greater frequency in the 
asthmatic group than the controls, but again this difference is not statistically significant 
(Table VI).
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Table VI ACE genotypes, allele distribution and serum ACE activity in asthmatic 
subjects and controls.
ASTHM ATICS (n=39) CONTROLS (n=78)
Frequency
(%)
ACE activity
(U/L)
F requency
(%)
ACE activity
(U/L)
ACE
GENOTYPE
DD 28.2 39.5 (23-62) 23.1 34.0 (20-47)
ID 66.7 24.5 (13-72) 55.1 27.0 (12-48)
II 5.1 18.5 (17-20) 21.8 20.0 (10-43)
ALLELE
FREQUENCY
D 61.5 50.6
I 38.5 49.4
Results for ACE activity are expressed as medians (range).
In the two groups studied, the control group were younger (p<0.05) than the 
asthmatic group by just over 9 years. In addition, although the age distribution for each 
genotype was similar for the control group, the DD genotype sub-group of the 
asthmatic subjects was significantly (p=0.003) older (mean [SD] age 58.6 [12.7] years) 
than the ID genotype sub-group (38.4 [15.0] years) and the II genotype sub-group 
(38.0 [22.6] years). These facts must be borne in mind when interpreting the results 
obtained, but may simply be a consequence of the relatively small sample size of the 
asthmatic group. In the asthmatic group it may be that older asthmatics with an 
exacerbation are more likely to require hospital admission than young asthmatics, thus 
skewing the age distribution.
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An additional analysis, not included in the original hypothesis, compared a 
group of acute hospital admissions with the control group. This group comprised the 
40 asthmatics and a further 20 non-asthmatic acute medical admissions on whom data 
was collected during the course of the study. When these two groups were compared 
there was again no difference in allele frequency or ACE genotype (Table VII).
Table V II ACE genotypes, allele distribution and serum ACE activity in hospital 
admissions and controls.
HOSPITAL
ADM ISSIONS
(n=39)
CONTROLS
(n=78)
Frequency
(%)
ACE activity
(U/L)
F requency
(%)
ACE activity
(U/L)
ACE
GENOTYPE
DD 27.1 59.0 (27-72) 23.1 34.0 (20-47)
ID 57.6 36.0(16-73) 55.1 27.0 (12-48)
II 15.3 22.0(11-54) 21.8 20.0 (10-43)
ALLELE
FREQUENCY
D 50.6 50.6
I 49.4 49.4
Results for ACE activity are expressed as medians (range).
However, when ACE activity was graphed against ACE genotype it was noted 
that the ACE activity was significantly higher (p=0.002) for the DD and ID genotype in 
the acute hospital admissions group than the control group. No difference was found 
for the II genotype (Figure 7). Once again there was a discrepancy in the ages of the 
two groups with the hospital admission group being older (mean [SD] age 48.9 [18.2] 
years) than the control group (35.6 [11.0] years). This finding must be interpreted with 
caution as this analysis was not a part of the original hypothesis.
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Figure 7 Serum ACE activity for acute hospital admissions and controls plotted
against ACE genotype.
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Open circles represent acute hospital admissions and black circles represent controls. 
Bars indicate median values. * p=0.002.
4.4 Conclusion
Thus the ACE gene insertion/deletion polymorphism has again been shown to 
determine serum ACE activity with the highest found for the DD homozygote and the 
lowest for the II homozygote with the ID heterozygote intermediate. There is a trend 
towards an increased frequency of the D allele in asthmatics but no association is found 
with activation of the renin-angiotensin system. There appears to be a higher ACE 
activity for the DD and ID genotypes in those individuals requiring hospital admission 
for an acute medical illness compared with a healthy control population.
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5. THE EFFECT OF ANGIOTENSIN II ON 
HISTAMINE-INDUCED BRONCHOCONSTRICTION 
IN THE HUMAN AIRWAY IN  VITRO
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5.1 Introduction
The active octapeptide hormone of the renin-angiotensin system, angiotensin II, 
is a potent vasoconstrictor and also causes weak bronchoconstriction when 
administered intravenously to mild asthmatics (132). Angiotensin II potentiates vagally- 
mediated contraction of rabbit airway smooth muscle via a prejunctional effect on 
cholinergic nerve terminals (44) and has a post-junctional potentiating effect on 
sympathetic contraction of rabbit saphenous artery (194-196). It also enhances tissue 
responses to noradrenaline (197).
Sub-threshold concentrations of angiotensin II enhance methacholine-induced 
bronchoconstriction both in vitro and in vivo (141) and endothelin-1-evoked 
bronchoconstriction of bovine airways in vitro, by a type-1 angiotensin II receptor- 
specific effect (26). The mechanism for this remains obscure but may be due to 
interaction with other spasmogens in the airway. The potent bronchoconstrictor 
histamine is released from mast cells in asthmatic airways and any interaction with 
angiotensin II would be of interest. This study examines the effect of angiotensin II at 
subthreshold doses for bronchoconstriction on histamine-induced bronchoconstriction 
in human airways in vitro.
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5.2 Materials And Methods
5.2.1 Tissue Collection and Preparation
Macroscopically normal human bronchi (3rd to 6th order) were obtained from 
eight patients undergoing thoracotomy for bronchial carcinoma All were smokers but 
information about pulmonary function was unavailable; none suffered from asthma. 
Bronchial rings were dissected free of connective tissue and fat and stored overnight at 
4°C in oxygenated Krebs-Henseleit solution of the following composition; NaCl 118.4 
mM, KC1 4.7 mM, CaCl2 2.5 mM, MgS04 1.2 mM, NaHC03 24.9 mM, KH2P04 1.2 
mM and glucose 11.1 mM. Published data has shown that overnight storage of this 
tissue does not alter its reactivity (198). Four bronchial rings were prepared from each 
specimen.
5.2.2 Measurement o f Contractile Responses
Contractile responses of bronchial rings (3-5mm) were measured in warmed
vertical organ baths (10ml) at 37±0.5°C in oxygenated (95% 02, 5% CO2 ) Krebs- 
Henseleit solution at pH 7.4. Tension was applied with an initial load of 3g via two 
platinum wires into the lumen. The rings were allowed to equilibrate gradually over a 
two hour period with adjustment of the tension to the desired load of 2g. Contractions 
were measured with a Grass polygraph force displacement transducer (Grass FT03T, 
Model 7, Quincy, Massachusetts, U.S.A.) which was calibrated with lg weight prior 
to use. One wire was anchored to the base of the organ bath and the other attached by a 
cotton thread to the transducer (Figure 8).
A baseline contraction for each tissue was measured by adding lO^M 
methacholine to ensure tissue reactivity and to measure maximal baseline contraction. 
Any tissue which failed to contract was discarded and replaced. The organ baths were 
then washed three times with Krebs-Henseleit solution, the rings allowed to equilibrate 
once more, then tension readjusted to a base load of 2g. Drugs were added directly to 
the organ baths. Cumulative concentration-response curves were constructed for each 
bronchial ring with four rings used from each specimen. The first curve was 
constructed using histamine alone to provide a control, adding concentrations of 10 ' 
9M, 3x10 ' 9M, 10 ' 8M, 3x10 ' 8M, 10 7M, 3x10 7M, 10 6M, 3x10 6M, 10 5M, 3x10 
'5M, 10 "4M and 3x10 ' 4M. These concentrations were equivalent to intervals of 0.5 
when transformed logarithmically. Each subsequent dose of histamine was added to the 
bath once the previous contraction had plateaued. Cumulative concentration-response 
curves were also constructed in the presence of angiotensin II which was added to the 
three other rings in a dose of 10 ' 7M, 3x10 ' 7M and 10 ‘ 6M respectively, 15 minutes
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before the subsequent addition of histamine in the doses described above. All contractile 
responses were calculated using a Linseis chart recorder and analysed subsequently.
It was not possible to construct individual control curves to histamine alone for 
each bronchial ring as histamine exhibits tachyphylaxis in vitro. It is not removed fully 
from receptor sites by washing, therefore constructing serial curves would lead to 
reduced tissue responsiveness. To compensate for this, the tension generated by each 
ring in response to histamine is expressed as a percentage of the maximal baseline 
contraction to methacholine. This is the accepted methodology for in vitro studies of 
this nature.
Figure 8 Apparatus used to measure the contractile responses o f bronchial rings.
Force T ransducer
Cotton thread
Water out
Krebs-Henseileit
solution
Bronchial ring
95% Oxygen
Water in (37°C)
Organ Bath
Polygraph 
Chart Recorder
5.2.3 Drugs
The drugs used were histamine (Sigma Chemicals, UK), methacholine chloride (Sigma 
Chemicals, UK) and angiotensin II (Sigma Chemicals, UK). All were prepared as a 
stock solution in distilled water then serial dilutions prepared in Krebs-Henseleit 
solution.
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5.2.4 Statistical analysis
Statistical significance was determined by two-way ANOVA with a probability level of 
p<0.05 considered significant.
5.3 R esults
Cumulative concentration-response curves were constructed for angiotensin II 
to ascertain the threshold for contraction. Angiotensin II produced small (<0.25 g 
maximum), concentration-dependent contractions of human bronchi, with a threshold 
of between 10'7Mand 10'6M (Figure 9). This compares with the maximum contraction 
of mean(SEM) 1.45 (0.28) g with 3xlO'4M histamine.
g
Figure 9 Cumulative concentration-response curve to angiotensin II at 1 O' M
to 10'5M  showing the contractile response as mean milligram tension 
generated.
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Number of observations (n) = 4. Bars represent SEM.
Pre-incubation with angiotensin II (10' 7M) evoked contraction in only three of 
the eight tissues and in all cases the contraction was less than 0.3 g compared with the 
control maximum contraction of mean 1.48 (0.21) g with histamine (3x10'4M).
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The results are shown in Tables VIII - X and Figures 10-12. Contractile 
responses are expressed as absolute values for gram weight tension generated (Figure 
10), as percentage of maximum contraction in response to histamine (Figure 11) and as 
percentage of baseline methacholine contraction (Figure 12).
Figure 10 Cumulative concentration-response curves to histamine alone and with 
angiotensin I I 10 7M, 3x10 7M  and 10 6M  as milligram weight tension 
generated.
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Control 
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Ang.II 3x10 -7M 
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log [Histamine] M
Number of observations, n=8.
Responses are shown as means with SEM error bars.
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Figure 11 Responses expressed as percentage o f histamine control maximum 
contraction.
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Fi gu r e 12 Responses expressed as percentage o f methacholine (10~4M ) evoked
contraction.
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These results clearly show no enhancement of histamine-evoked contractions
-9 -4
(10 M - 3 x 10 M) in any of the tissues following pre-incubation with angiotensin II 
at 10 -7M, 3 x 10 7 M and 10 6M.
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Table VIII Results from the cumulative concentration response curves as milligram 
weight tension generated.
[Histamine] Control Ang.II 10 M Ang.II 3 x l OM Ang.II 10°M
6.2 0 2.5 0
10 \1 (6.2) (0) (2.5) (0)
32.5 33.8 41.0 108.1
3x10 ■’M (25.0) (31.0) (29.1) (78.4)
40.6 57.5 46.0 126.2£00o (24.7) (36.7) (29.5) (92.8)
72.5 91.2 61.0 145.0
3x10 8M (29.0) (38.2) (29.2) (102.0)
96.2 125.0 88.9 175.6
10 7M (38.5) (46.7) (32.6) (115.1)
186.2 180.0 146.1 228.8
3x10 7M (44.8) (65.4) (43.0) (131.3)
368.8 310.0 292.8 318.1
10 6M (81.8) (88.2) (64.9) (138.8)
643.1 582.5 520.1 483.8
3x10 6M (117.0) (147.6) (89.0) (160.4)
1026.9 918.8 793.8 767.5
10 5M (135.8) (236.9) (109.3) (178.5)
1303.1 1177.5 954.1 963.1
3x10 5M (149.3) (317.0) (123.9) (181.3)
1423.1 1343.8 1045.4 1081.2
10 4M (177.9) (386.0) (144.6) (193.2)
1476.2 1400.6 1045.4 1060.6
3x10 4M (205.5) (417.1) (148.1) (189.3)
Results are expressed as mean (SEM).
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Table IX  Results from the cumulative concentration response curves as percentage
o f histamine control maximum contraction.
[Histamine] Control Ang.II 10 '7M Ang.II 3xlO M Ang.II 10°M
0.2 0 0.2 0
10 9M (0.2) (0) (0.2) (0)
1.5 1.4 1.9 6.8
3x10 -9M (1.0) (1.2) (1.1) (5.4)
2.3 2.8 2.2 8.0200o (1.0) (1.5) (1.2) (6.4)
4.8 5.2 3.2 9.5
3x10 8M (1.5) (1.9) (1.3) (7.0)
6.0 7.6 5.6 12.9
10 7M (1.6) (2.0) (1.4) (8.0)
12.2 11.1 9.4 16.6
3x10 7M (2.4) (3.0) (1.9) (9.0)
24.8 19.9 18.7 22.1
10 6M (4.7) (3.9) (2.5) (9.3)
44.5 37.6 33.7 32.3
3x10 6M (6.7) (6.6) (3.8) (10.2)
70.4 59.9 52.8 51.9
10 5M (5.5) (14.0) (4.7) (10.8)
89.2 75.9 64.6 65.4
3x10 5M (3.5) (18.9) (5.9) (10.4)
95.8 86.6 70.4 73.2
10 4M (1.3) (24.5) (7.6) (11.2)
98.1 89.3 70.1 72.0
3x10 4M (1.3) (26.2) (8.0) (11.2)
Results are expressed as mean (SEM).
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Table X Results from the cumulative concentration response curves as percentage
baseline methacholine (104M) contraction.
[Histamine] Control Ang.II 10 M Ang.II 3x10''M Ang.II 10°M
0.3 0 0.2 0
10 9M (0.3) (0) (0.2) (0)
1.9 2.7 3.9 9.2
3x10 9M (1.4) (2.0) (2.7) (5.3)
3.4 4.7 4.2 10.6
10 8M (1.5) (2.6) (2.7) (6.2)
7.4 7.4 5.2 12.4
3x10 8M (2.8) (2.7) (2.6) (6.7)
9.2 12.6 8.4 15.8
10 7M (2.8) (3.8) (2.9) (7.5)
18.8 18.3 15.2 21.2
3x10 7M (4.0) (5.3) (3.4) (8.7)
36.7 34.1 33.2 33.9
10 6M (7.4) (8.7) (7.1) (10.1)
65.8 65.7 58.5 54.9
3x10 6M (13.9) (16.1) (11.5) (14.0)
104.6 99.6 99.5 95.0
10 5M (19.3) (27.3) (27.4) (22.8)
130.8 125.3 118.1 121.9
3x10 5M (22.1) (36.3) (30.2) (29.7)
140.4 140.0 126.9 136.4
10 4M (22.9) (42.7) (32.0) (33.4)
144.6 142.4 126.4 133.3
3x10 4M (24.3) (43.9) (32.2) (32.8)
Results are expressed as mean (SEM).
5.4 Conclusion
These results show angiotensin II has no effect on histamine-induced 
contraction of human bronchial rings in vitro.
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6. THE EFFECT OF ANGIOTENSIN II ON 
HISTAMINE-INDUCED BRONCHOCONSTRICTION 
IN MILD ASTHMATIC SUBJECTS
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6.1 Introduction
In the asthmatic airway, bronchoconstriction is the end result of a complex 
series of interactions of the effects of neural stimuli and both circulating and locally 
released bronchoconstrictor agents. These include inflammatory mediators, peptides, 
catecholamines and cytokines. In addition to the direct bronchoconstrictor effects of 
these agents, some also act in synergy with other agents thus increasing the final degree 
of bronchoconstriction. Humoral modulation of neurally mediated bronchoconstriction 
involves a number of agents including prostaglandins, acetylcholine, noradrenaline, 
adrenaline, nitric oxide, histamine, serotonin and bradykinin (22).
Angiotensin II has synergistic effects pre-junctionally on cholinergic nerves 
(44), post-junctionally on sympathetic nerves (194-196) and enhances the effects of 
noradrenaline (197). Previous work has shown that sub-threshold concentrations of 
angiotensin II enhance the effects of methacholine on human airways in vitro and in 
vivo (141) and endothelin-1 on bovine airways in vitro (26). Since circulating 
angiotensin II is elevated in acute severe asthma this potentiating effect may be clinically 
relevant.
Angiotensin II may interact with other mediators of bronchoconstriction such as 
histamine. Chapter 5 has examined the effect of angiotensin II on histamine-induced 
bronchoconstriction in human bronchial rings in vitro and this study investigates the 
effect of subthreshold doses of angiotensin II on histamine-induced bronchoconstriction 
in vivo in subjects with mild asthma.
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6.2 Materials And Methods
6.2.1 Patients
Eight volunteers (5 male) with mild asthma were recruited. Their mean (range) 
age was 41 (27-69) years and their baseline FEVj was 88 (78-106) % of predicted. 
Bronchial hyper-responsiveness to inhaled histamine was demonstrated by challenge 
testing according to the method of Cockcroft et d. (199). Individuals were excluded if 
found to be hypertensive, pregnant or taking antihistamines, diuretics or angiotensin- 
converting enzyme inhibitors. Two subjects were smokers and one was a former 
smoker. Seven subjects were taking inhaled salbutamol as required, four were taking 
additional low dose (<1,000 pg daily) inhaled beclomethasone dipropionate, one was 
taking additional salmeterol and one was on no treatment (Table XI).
Table XI Study subject characteristics.
Sex Age
(yrs)
FEVj
Litres [% predicted]
Histamine
PC,n(mg/ml)
Treatment BP
(mmHg)
1 M 27 4.80 [106%] 1.84 S 128/74
2 M 49 3.56 [88%] 4.21 nil 157/89
3 M 32 2.75 [82%] 3.24 S/BDP 134/68
4 F 35 2.83 [98%] 1.26 S/BDP 134/79
5 F 56 2.14 [79%] 2.61 S/BDP 148/88
6 M 30 4.37 [97%] 7.75 S 132/76
7 F 30 2.46 [80%] 5.32 S 132/78
8 M 68 2.46 [78%] 6.33 S/BDP/Sm 153/83
Mean 4 0 .9 3.18 [88.5%] 3 .48*
(SD) (15.0) (0.97) (10.6)
Abbreviations: S = salbutamol (prn), BDP = beclomethasone dipropionate (<1,000 
pg/day), Sm = salmeterol, * = geometric mean.
Prior to each study day subjects were instructed to withhold short-acting beta- 
agonists for 8 hours and long-acting beta-agonists for 12 hours but inhaled 
corticosteroids were continued unchanged.
Ethical approval for the study was obtained from the Glasgow West Ethical 
Committee and written informed consent was obtained from the study volunteers prior 
to commencing the study (Appendix 3).
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6.2.2 Study Protocol
The study was carried out in a randomised, double-blind and placebo-controlled 
manner. The subjects attended the laboratory on four separate occasions; initially a 
screening visit comprised a physical examination followed by a histamine bronchial 
provocation test. This was performed using a Wright’s nebuliser, calibrated to give an 
output of 0.12 ml/min. at a flow rate of 8 1/min. air, to define the concentration required 
to cause a 20% fall in FEVj from baseline (the PC20 histamine). On the three 
subsequent visits an intravenous cannula (Venflon, Viggio AB, Helsinborg, Sweden) 
was inserted into a vein on each forearm then, after 30 minutes rest, a blood sample 
was extracted to measure baseline plasma renin and angiotensin II levels. Baseline 
spirometry, pulse, blood pressure and pulse oxymetry were measured then an 
intravenous infusion commenced via a 50ml syringe driver (Perfusor Secura E, B.B. 
Braun, Melsunger AG, Germany). Subjects received either placebo (5% dextrose) or 
subthreshold doses of angiotensin II at 1 or 2 ng/kg/min over one hour. After 30 
minutes, steady state was deemed to have been reached and a further blood sample was 
taken from the arm opposite to the infusion and the FEV1 repeated. A histamine 
bronchial provocation test was then performed and the PC20 noted. At the completion of 
the test a further blood sample was taken and the bronchoconstriction reversed with 
nebulised salbutamol (Ventolin, Allen and Hanburys, UK). Throughout the study 
pulse, blood pressure and oxygen saturation were monitored at 15 minute intervals.
6.2.3 Measurements
6.2.3.1 FEVj
Spirometry was measured using a dry wedge spirometer (Vitalograph Model S, 
Buckinghamshire, U.K.), the highest of three measurements being taken at each time 
point.
6.2.3.2 Pulse and Blood Pressure
A semi-automatic sphygmomanometer (Dinamap, 1846SX Vital Signs Monitor, 
Critikon, Florida, USA) was used to measure pulse and blood pressure from the 
opposite arm to the infusion at each time point.
6.2.3.3 Oxygen Saturation
Oxygen saturation was measured by transcutaneous pulse oxymetry (Oscaroxy Pulse 
Oxymeter, Datex, Helsinki, Finland) at each time point.
72
6.2.3.4 Histamine Bronchial Provocation Test
Baseline spirometry was carried out then repeated after a two minute inhalation of 0.9% 
saline, administered via a Wright’s nebuliser driven by compressed air calibrated to give 
an output of 0.12 ml/min at a flow rate of 8 1/min. Doubling doses of histamine were 
subsequently administered starting with a dose of 0.0625 mg/ml. The FEVj was 
measured at 30, 90 and 180 seconds following each inhalation until a 20% fall was 
achieved. The histamine concentration causing a 20% fall in FEVj was calculated by 
linear regression and taken as the PC 20.
6.2.3.5 Angiotensin II Assay
This was performed as described in Chapter 3 (Section 3.2.3.2) (189). The intra-assay 
coefficient of variation is 6.4% and inter-assay variation 10%. The reference range for 
our laboratory is 3-12 pg/ml (2.9-11.5 x 10_9M).
6.2.3.6 Renin Assay
This was performed as described in Chapter 3 (Section 3.2.3.1) (188). The intra-assay 
coefficient of variation is 5.5% and the inter-assay variation 11%. The reference range 
for our laboratory is 9-50 pU/ml.
6.2.4 Drugs
The drugs used were histamine (Fluka Chemicals, UK) and angiotensin II (Sigma 
Chemicals, UK). Serial dilutions of histamine were prepared in phosphate buffered 
saline ranging from 0.0625-8.0 mg/ml. Angiotensin II was prepared in 5% dextrose 
under sterile conditions and blinded by Ms. W. Fallon in our Pharmacy Department.
6.2.5 Statistical analysis
Statistical significance was determined by one-way ANOVA with a probability level of 
p<0.05 considered significant. Histamine PC20 values were transformed logarithmically 
prior to statistical analysis.
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6.3 R esults
On each of the three study days there was no significant difference between 
baseline pulse, blood pressure, oxygen saturation, FEVP plasma renin and plasma 
angiotensin II measurements (TableXII).
Table XII Baseline measurements.
Study Day : Screening Placebo Angiotensin
II
lng/kg/m in .
Angiotensin
II
2ng/kg/m in.
FEVt 3.18 3.07 3.12 3.01
(litres) (0.34) (0.28) (0.28) (0.30)
Pulse 62.2 58.5 60.2 62.0
(bpm) (3.1) (2.2) (3.1) (3.4)
Systolic BP 139.8 132.2 135.2 130.1
(mmHg) (3.9) (2.6) (4.0) (5.5)
Diastolic BP 79.4 73.8 77.1 73.2
(mmHg) (2.5) (2.9) (2.2) (2.9)
0 2 Saturation 96.9 97.1 96.8 96.2
(%) (0.4) (0.3) (0.2) (0.2)
Renin 16.9 9.6 9.4
(14 U/ml) (7.0) (1.9) (2.2)
Angiotensin II 7.6 7.3 8.2
(pg/ml) (1.6) (1.5) (1.9)
[Molar concentration] [7.3 xlO M] [7.0 xlO M] [7.9 xlO'9M]
Results are expressed as mean (SEM)
Prior to histamine challenge and during the infusion there was no significant 
change in FEVj noted from baseline values on each study day; mean [SEM] change in 
FEV\ (litres) from baseline: placebo -0.08 [0.05], angiotensin II lng/kg/min. -0.12 
[0.04], angiotensin II 2ng/kg/min. -0.08 [0.04].
Following histamine bronchial provocation testing on each study day there was 
no significant difference in histamine PC20 (geometric mean [range]) between screening 
(3.48 [1.26-7.75] mg/ml), placebo (2.67 [0.89-9.57] mg/ml), angiotensin II 1 
ng/kg/min. (2.45 [0.42-6.97] mg/ml) and angiotensin II 2 ng/kg/min. (3.09 [0.88- 
10.78] mg/ml) study days (Figure 13).
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Figure 13 Histamine PC20 value on each study day.
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A significant rise (p<0.05) in both systolic and diastolic blood pressure 
occurred following angiotensin II infusion on the angiotensin II 1 ng/kg/min and 2 
ng/kg/min compared to placebo (systolic BP mean [SEM] mmHg 121.4 [4.57], 139.4 
[6.72] and 140.5 [5.84], and diastolic BP mean [SEM] mmHg 72.0 [2.40], 81.4 
[2.54] and 82.88 [2.43] on placebo, angiotensin II lng/kg/min and angiotensin II 
2ng/kg/min study days respectively). However this difference in blood pressure was no 
longer evident following histamine challenge testing on each study day (Figure 14). 
This may reflect the vasodilating effect of histamine with a rise in blood pressure on the 
placebo days due to the stress associated with bronchoconstriction and the perception of 
dyspnoea. No changes were noted in pulse rate or oxygen saturation throughout each 
study day.
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Figure 14 Changes in blood pressure during the period o f infusion by study day.
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* Denotes a significant difference between placebo and both angiotensin II infusion days 
(p < 0.05).
Plasma angiotensin II was measured at baseline, steady state (30 minutes into 
the infusion) and following completion of the infusion on each study day. On the 
placebo day angiotensin II levels remained unchanged; mean (SEM) [mean molar 
concentration] baseline 7.6 (1.6) pg/ml [7.3 x 10'9M], steady state 5.7 (1.1) pg/ml [5.5 
x 10' 9M] and post-histamine challenge 5.4 (0.6) pg/ml [5.2 x 10' 9M]. On both 
angiotensin II study days plasma levels increased significantly (p<0.05) after 30 
minutes compared to baseline and placebo, moreso on the 2ng/kg/min. day and 
remained elevated until the end of the infusion; 7.3 (1.5) pg/ml [7.0 x 10' 9M], 23.8 
(3.7) pg/ml [2.3 x 10' 8M] and 22.0 (4.3) pg/ml [2.1 x 10' 8M] after angiotensin II 
lng/kg/min. and 8.2 (1.9) pg/ml [7.9 x 10' 9M], 46.2 (4.7) pg/ml [4.4 x 10' 8M] and 
36.0 (5.2) pg/ml [3.5 x 10'8M] after angiotensin II 2 ng/kg/min (Figure 15).
No adverse effects were reported by the subjects on any of the study days.
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Figure 15 Plasma angiotensin II levels measured before, during infusion and
following histamine challenge testing on each study day.
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**Denotes a significant difference from placebo and angiotensin II lng/kg/min 
(p<0.05).
6.4 Conclusion
In summary, an infusion of angiotensin II at sub-threshold doses for 
bronchoconstriction causes a rise in blood pressure and plasma angiotensin II levels but 
has no effect on histamine-induced bronchoconstriction in mild asthmatic volunteers.
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7. THE EFFECT OF ANGIOTENSIN II ON 
REMODELLING OF THE RAT AIRWAYS AND 
MESENTERIC VASCULATURE
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7.1 Introduction
In chronic asthma, airway remodelling contributes to airflow obstruction by 
causing hypertrophy and hyperplasia of airway smooth muscle (200), increased volume 
of mucous glands, epithelial loss (48) and subepithelial fibrosis (49, 50). The 
mechanism of these structural changes is incompletely understood but recent evidence 
implicates growth promoters in airway smooth muscle cell proliferation (201).
Cardiovascular growth and remodelling occurs in a variety of cardiac and 
arterial diseases. One of the most important growth promoters is the renin-angiotensin- 
aldosterone system (145). Angiotensin II stimulates vascular smooth muscle cell 
growth both in vitro (148) and in vivo (151, 154), and promotes growth of fibroblasts 
and cardiac myocytes (202). Recent in vitro work has shown that angiotensin II induces 
human airway smooth muscle cell proliferation and hypertrophy (101).
Since plasma angiotensin II levels are raised in acute severe asthma (132) and in 
response to p2-agonists (142, 143), and angiotensin II infusion is known to cause 
bronchoconstriction (132) it could be an important growth promoter in airway 
remodelling. However, the effects of angiotensin II on the growth of airway smooth 
muscle cells and other components of the airway wall have not yet been explored in 
vivo.
This study examines the effect of infused angiotensin II on the growth of 
smooth muscle, epithelium and connective tissue in the rat airway in vivo. The response 
of the airways is compared to the mesenteric vasculature, where angiotensin II is a 
known growth promoter (186).
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7.2 Materials And Methods
Fourteen young male Wistar rats (weight 250-320g) were randomly allocated to 
an experimental (n=7) and a control group (n=7). Over fourteen days, all animals 
received a continuous subcutaneous infusion of the thymidine analogue, bromo-2'- 
deoxyuridine (BrdU) [Sigma Chemicals, U.K.] at a dose of 210 jig/kg/hr. BrdU is 
taken up by cells undergoing DNA synthesis, either during replication or repair of 
damaged DNA, therefore both hypertrophy and hyperplasia of cells will result in 
increased uptake of BrdU. The experimental group also received angiotensin II 
(Hypertensin, Ciba Geigy, Basle, Switzerland) at a dose of 200 ng/kg/min., while 
control animals received only normal saline. All solutions were administered via 
osmotic minipumps (ALZET Model No. 2002, ALZET Corporation Ltd., California, 
U.S.A.) implanted subcutaneously in the neck under halothane anaesthesia by Dr. C. J. 
Kenyon.
After two weeks, the animals were sacrificed by stunning then decapitation to 
avoid activating the renin-angiotensin system. Trunk blood was collected for plasma 
renin and angiotensin II analysis. Systolic blood pressure, measured by an automated 
tail cuff method (203), weight and pulse rate were documented prior to and on 
completion of the experiment.
The left lung was inflated in situ via the trachea with 10% neutral buffered 
formalin at a pressure of 25 cm of water then fixed overnight. Transverse, coronal 
slices were obtained from the perihilar and basal regions of the lung. The kidneys and 
mesentery were also removed, fixed in formalin, then all tissues were processed for 
histological examination.
7.2.1 Immunostaining for BrdU
Lung and mesentery sections, 3|im  thick, were prepared then underwent 
microwave antigen retrieval followed by immunocytochemistry with a mouse 
monoclonal anti-BrdU antibody (Bionuclear Services Ltd., Bude, Cornwall, U.K.) 
following a modification of a standard alkaline phosphatase anti-alkaline phosphatase 
(APAAP) technique described fully in Appendices 4 & 5 (Figure 16). Control sections 
had mouse IgG substituted for the primary antibody. To define the anatomy, lung 
sections were counter-stained with periodic acid-Schiff reagent (PAS) and the 
mesentery sections with alcian blue-PAS.
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F ig u re  16 Rat lung demonstrating airway and artery stained with anti-BrdU 
monoclonal antibody.
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BrdU uptake is shown in the epithelium (small arrowhead), airway smooth muscle 
(long arrow), adventitia (short arrow) and arterial media (large arrowhead).
7.2.2 In Situ Hybridisation for Renin m RN  A
Digoxygenin-labelled riboprobes (1200 bp) were prepared from a cDNA 
complementary to most of the coding sequence of rat renin mRNA. Kidney sections, 
3pm  thick, were cut onto 3-amino-propyl-triethoxy-silane coated glass slides and a 
digoxygenin-labelled rat renin riboprobe (1 in 50 dilution) was applied and left to 
hybridise overnight at 42 °C. Hybridisation was revealed by applying mouse anti- 
digoxin monoclonal antibody (Sigma, U.K.) as described fully in Appendix 6. 
Negative control sections were hybridised with “sense” riboprobes and buffer 
substituted for riboprobes.
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Figure 1 7 Rat airway stained with a-smooth muscle actin.
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Airway smooth muscle cells are labelled brown (Arrowhead).
7.2.3 Morphometry
Two lung sections per animal were stained with Masson’s trichrome and 
smooth muscle identified by immunocytochemistry using a-smooth muscle actin 
antibodies (Sigma, U.K.) [Figure 17] according to the method in Appendix 4. All 
transversely cut airways (i.e. with length:breadth ratio < 2.0) were measured in a 
blinded fashion as follows: outlines of the internal perimeter, epithelial basement 
membrane, bronchial smooth muscle internal and external boundaries, and the outer 
adventitial perimeter (Figure 18) were traced using a camera lucida (Wild, Heerbrug, 
Switzerland). The tracings were digitised using a camera (JVC TK-870E) linked to an 
automated computerised image analysis system (Optomax V, IBM PS/2 8570, 
Analytical Instruments, Cambridge, U.K.). The area occupied by the epithelium, 
bronchial smooth muscle and adventitia, and the length of the internal perimeter were 
calculated using Vids-V software (Analytical Instruments, U.K.). To correct for 
shrinkage artifact during processing the calculated areas were transformed by square 
root and plotted against the length of the internal perimeter for that airway. The internal
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perimeter has been shown previously to remain constant despite any shrinkage which 
occurs in the tissues (204).
F igure 18 Tracing o f a rat airway section showing the tissue boundaries measured 
by morphometry.
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Morphometry of the mesenteric arteries and veins was performed on sections 
stained with elastica-Martius’ scarlet blue which defines the internal and external elastic 
laminae and distinguishes arteries from veins. These were examined by Mr. Niall 
Whyte. For each animal all intact arteries and veins within one section of the entire 
mesentery were measured by a technique that is a modification (205) of the method of 
Short (206). In brief, six Cartesian co-ordinates were recorded for each vessel: two 
delineating the longest diameter, two the shortest internal diameter and two the shortest 
external diameter of the media (Figure 19). These co-ordinates enable the wall thickness 
and wall-lumen ratio to be calculated, even in obliquely sectioned vessels.
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Figure 19 Diagram illustrating the six points measured for morphometry o f the
mesenteric vasculature.
7.2.4 DNA Synthesis
In each airway the total number of nuclei in the epithelium, smooth muscle and 
connective tissue were counted. In small airways all nuclei were counted. In larger 
airways a maximum of 300 nuclei were counted for each cell type. The number of 
BrdU-positive nuclei in each tissue was expressed as a percentage of the total number 
of nuclei creating a BrdU index. In the mesenteric blood vessels, the BrdU index was 
similarly assessed in medial smooth muscle cells.
7.2.5 Blood Samples
Plasma renin activity was measured in trunk blood collected into heparinised 
containers then separated by centrifugation at 3,000 g for 15 minutes and frozen at -20 
°C until analysis. This was performed by a radioimmunoassay of angiotensin I 
generated from a known amount of renin substrate and expressed as ng/ml/hour (207). 
Blood samples for angiotensin II were assayed as described in Chapter 3 (Section 
3.2.3.2) (189).
7.2.6 Observer Variation
Intra-observer variation was tested by counting the epithelial, smooth muscle 
and adventitial cells in 32 randomly selected airways in a blinded manner on two 
separate occasions giving a Pearson product moment correlation coefficient of 0.98, 
and for morphometric measurements a correlation coefficient of 1.0. Inter-observer 
variation was tested by two observers counting cells in 10 randomly selected airways 
giving a correlation coefficient of 0.92.
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7.2.7 Statistical Analysis
Group values for blood pressure, heart rate and weight were compared using 
Student’s t-test. Plasma renin and angiotensin II levels were compared using the Mann- 
Whitney U-test. Comparison of the BrdU indices between the two groups was 
performed by calculating the mean values for each animal then comparing the two 
groups of rats by Student’s t-test.
The square root of the area of each component of the airway wall was plotted 
against the length of the internal perimeter and a regression analysis performed for each 
animal (208). The values of the slope and intercept with the y-axis were grouped for the 
control and the experimental animals then compared by Student’s t-test.
Changes in the geometry of the mesenteric vessels were assessed by plotting 
cumulative distribution curves of the wall-lumen ratio for the arteries and veins.
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7.3 R esu lts
There was no difference in any parameter between the two groups of animals 
prior to commencing the study (Table XIII). Blood pressure rose in the group infused 
with angiotensin II to a mean (SD) level of 197.1 (22.5) mmHg [p = 0.0001] but no 
change in blood pressure occurred in the control group. The angiotensin II group were 
heavier following the study, probably reflecting fluid retention secondary to aldosterone 
release.
There was a trend towards a lower plasma renin activity in the angiotensin II 
infused animals although this did not attain statistical significance. The plasma levels of 
angiotensin II were not significantly different in the control and angiotensin II infused 
animals (Table XIII).
Table X III Physiological measurements in the control and angiotensin II animals 
before and after the two week infusion.
Control G roup Angiotensin II G roup
Pre-infusion Post-infusion Pre-infusion Post-infusion
Blood Pressure 126.3 139.4 134.9 197.1*
(mmHg) (14.7) (12.4) (14.7) (22.5)
Renin Activity 0.88 0.33
(ng/ml/hr) (0.7-2.7) (0.1-0.9)
Angiotensin II 65.0 78.0
(pg/ml) (34-125) (48-110)
Heart Rate 406.1 427.0 422.9 404.0
(bpm) (36.5) (37.8) (31.7) (38.9)
Weight 288.0 316.4 290.3 321.9 |
(g> (22.5) (28.5) (10.9) (11.6)
Results are given as mean (standard deviation) except for plasma renin activity and 
angiotensin II which are expressed as median (interquartile range).
* Denotes p < 0.01 compared to the pre-infusion value and to the control group, 
t  Denotes p < 0.01 compared to pre-infusion value.
7.3.1 In Situ Hybridisation
In situ hybridisation revealed almost complete suppression of renin mRNA 
expression in the juxta-glomerular apparatus in the animals receiving angiotensin II 
(Figure 20) as shown by the median [inter-quartile range] glomerular labelling index 
(0.79 [0-1.2]) compared to the control animals (50.2 [47-60.2]) [p=0.002] (Figure 21).
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F igure  20 In situ hybridisation o f rat kidney showing suppression o f renin mRNA 
expression in juxtaglomerular cells following angiotensin 11 infusion .
F igure  21 In situ hybridisation o f rat kidney showing normal renin mRNA 
expression in control animals.
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7.3.2 DNA Synthesis
In the airways, there was no difference in the BrdU indices of any of the 
components of the airway wall between the two groups of animals: epithelium - control 
group mean [SEM] 16.7 [2.3]%, angiotensin II group 16.0 [2.2]%; airway smooth 
muscle - control group 8.6 [1.1]%, angiotensin II group 9.3 [1.1]%; adventitia - 
control group 26.4 [2.2]%, angiotensin II group 26.6 [2.4]% (Figure 22).
Figure 22 Comparison o f DNA synthesis between the control and angiotensin II-
infused animals.
□  CONTROL
ANGIOTENSINII
EPITHELIUM ADVENTITIA MUSCLE ARTERIES VBNS
Values are expressed as mean ± SEM. * p=0.03 compared to control animals.
In the mesenteric arteries, the BrdU index was significantly higher in the 
animals receiving angiotensin II (mean [SEM] 18.4 [2.3] %) compared to the control 
animals (9.4 [2.8]%) [p = 0.028]. There was no difference between the BrdU index in 
the veins: angiotensin II group (12.0 [2.9]%), control group (11.4 [2.6]%) (Figures 22 
& 23).
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Fi gure 2 3  Transverse section o f rat bronchial artery.
BrdU uptake is seen in medial smooth muscle cell nuclei (Arrowhead).
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7.3.3 Morphometry
Morphometry showed no difference in the volume of the airway wall occupied 
by epithelium, smooth muscle and adventitia between the two groups of animals (Table 
XIV).
Table XIV Slopes and intercepts from linear regressions o f the square root o f areas 
o f airway wall tissues against internal perimeter.
Control Group 
(n=7)
Angiotensin II Group 
(n=7)
Slope
Epithelium 0.08 (0.006) 0.07 (0.006) p=0.09
Smooth Muscle 0.09 (0.005) 0.08 (0.009) p=0.29
Adventitia 0.16 (0.01) 0.14 (0.02) p=0.53
Intercept
Epithelium 31.4 (4.0) 38.0 (3.9) p=0.27
Smooth Muscle 10.9 (2.9) 16.8 (7.7) p=0.50
Adventitia 8.7 (12.0) 5.9 (20.0) p=0.91
Results are expressed as mean (SEM) with ‘p’ values are given for the test of equality 
of the two groups.
Cumulative distribution curves of wall thickness showed that the arteries in the 
angiotensin II infused animals were thicker than those in the controls but this difference 
was not statistically significant. There were no changes in the veins.
7.4 Conclusion
Therefore, a two week infusion of angiotensin II in Wistar rats causes a rise in 
blood pressure and weight gain with suppression of renin mRNA expression in renal 
juxta-glomerular cells. There is increased DNA synthesis in the media of the mesenteric 
arteries but no evidence of DNA synthesis or remodelling in the rat airway.
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THE EFFECT OF SODIUM DEPLETION ON 
REMODELLING OF THE RAT AIRWAY
8.1 Introduction
In Chapter 7 I have shown that a two week infusion of angiotensin II has no 
effect on rat airway remodelling. However, systemic administration of exogenous 
angiotensin II may not be as physiologically relevant as elevation of endogenous levels; 
homeostatic regulatory mechanisms may compensate, at least in part, for the infusion of 
angiotensin II or local airway levels may not be raised. This study examines the effect 
of endogenous activation of the renin-angiotensin system by sodium depletion on 
airway remodelling in a rat model previously shown to induce remodelling of the 
mesenteric arteries (186).
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8.2 M ethods
Twelve young male Sprague-Dawley rats were randomised to two groups (each 
n=6). All animals received 2 week infusions of the thymidine analogue bromo-2'- 
deoxyuridine (BrdU) [Sigma Chemicals, U.K.] 1.25 mg/day via subcutaneous osmotic 
minipumps (ALZETModel No. 2002, ALZET Corporation Ltd., California, U.S.A.). 
The osmotic minipumps were implanted subcutaneously in the neck of the animal under 
halothane anaesthesia by Dr. C. J. Kenyon.
The experimental group were fed a low salt diet (10 mmol Na+) [Special Diets 
Services] and the control group were fed normal rat chow. After two weeks, the 
animals were sacrificed by stunning then decapitation. Trunk blood was collected for 
analysis of plasma renin activity and aldosterone.
The lungs, kidneys and mesenteric vascular bed were dissected out and 
immersion-fixed in formalin. The mesenteric vessels have been examined previously 
and the results reported in abstract form (186). The lungs and kidneys were processed 
for histological examination and embedded in wax. Immunocytochemistry was 
performed as outlined in Appendix 5 with an anti-BrdU monoclonal antibody 
(Boehringer Mannheim). The BrdU index was calculated for each tissue by expressing 
the number of BrdU-positive nuclei as a percentage of the total number of nuclei 
counted.
In situ hybridisation was performed according to the method described in 
Appendix 6 with a digoxygenin-labelled renin riboprobe to demonstrate renin mRNA 
expression in kidney sections. The glomerular labelling index was calculated by 
expressing the number of renin-positive cells as a proportion of the total number of 
glomeruli.
Morphometry of the airways was carried out on all transversely cut airways as 
described in Chapter 7 (Section 7.2.3).
Inter- and intra-observer variation were as stated in Chapter 7 (Section 7.2.6). 
All analyses were performed in a blinded fashion in every case with each animal having 
been assigned a code number which was not decoded until all data had been collected.
93
8.3 R esults
Minor insignificant variations in blood pressure (5-10 mmHg) were seen 
between the two groups. The differences in the BrdU indices of the three tissues in the 
control and sodium depleted animals were not statistically significant. Control animals: 
mean [SEM] BrdU index: epithelium 10.8 [3.0] %, smooth muscle 10.9 [2.8] %, 
adventitia 18.0 [3.6]. Sodium depleted animals: epithelium 7.4 [2.8] %, smooth muscle 
5.6 [1.8], adventitia 11.2 [2.8] (Figure 24).
Figure 24 Comparison o f DNA synthesis between sodium depleted and control
animals.
25 -i
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Morphometry showed no difference in the volume of airway smooth muscle, 
epithelium or adventitia between the 2 groups (Table XV).
Table X V Slopes and intercepts from linear regressions of the square root of area 
of airway wall tissues against internal perimeter.
Control Group Sodium Depleted 
Group
Slope
Epithelium 0.09 (0.005) 0.11 (0.02) p=0.22
Smooth Muscle 0.08 (0.009) 0.08 (0.02) p=0.92
Adventitia 0.08 (0.02) 0.08 (0.01) p=0.90
Intercept
Epithelium 41.25 (3.7) 30.1 (7.3) p=0.21
Smooth Muscle 33.15 (4.7) 33.37 (7.3) p=0.98
Adventitia 57.35 (7.2) 52.25 (9.7) p=0.68
Results are expressed as mean (SEM) with ‘p’ values given for test of equality of the 
two groups.
Plasma renin activity & aldosterone were significantly higher (p < 0.05) in the 
sodium depleted rats (mean [SEM] plasma renin activity 1.28 [0.32] ng/ml/hr, plasma 
aldosterone 1.28 [0.44] nM) than in the control animals (plasma renin activity 0.52 
[0.08] ng/ml/hr, plasma aldosterone 0.48 [0.12] nM) (Figure 25).
Figure 2 5 Plasma renin activity and aldosterone levels in sodium depleted and 
control animals.
2  - i
*p<0.05
a
£3 Plasma Renin Activity 
H  Plasma Aldosterone
Control Sodium Depleted
* Denotes significantly (p < 0.05) higher levels of plasma renin activity and aldosterone 
in sodium depleted animals compared to controls.
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In the kidneys, renin mRNA expression was significantly greater (p < 0.01) in 
the sodium depleted group than in the controls as calculated from the glomerular 
labelling index: Mean (SEM) glomerular labelling index 62.5 (5.8) % in sodium 
depleted animals and 37.4 (4.7) % in controls (Figure 26).
Figure 26 Glomerular labelling index in the renal juxta-glomerular cells of the 
sodium depleted and control animals.
80 - i
p<0.01
x
<L> 60 -
«  40  -
40
2 0 -
£
O
Control Sodium Depleted
8.4 Conclusion
Therefore, a two week dietary sodium restriction in Sprague-Dawley rats causes 
endogenous activation of the circulating renin-angiotensin system, increased plasma 
renin activity and plasma aldosterone, with an associated increase in renin mRNA 
expression in renal juxta-glomerular cells but no significant DNA synthesis or 
remodelling in the rat airway.
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9. EVIDENCE FOR THE EXISTENCE OF A LOCAL 
RENIN-ANGIOTENSIN SYSTEM IN THE HUMAN LUNG
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9.1 Introduction
The renin-angiotensin system plays a role in acute asthma (132), 
bronchoconstriction (26, 132, 141), pulmonary vasoconstriction (157) and is a growth 
promoter for human airway smooth muscle cells in vitro (101). Most tissues that 
respond to the circulating renin-angiotensin system also have the capacity to synthesise 
its components: local systems are present in the kidney, heart, brain, vasculature, 
adrenal glands, gonads(156) and salivary glands (126).
Components of the renin-angiotensin system have been identified in lung tissue 
in various species, specifically ACE (159), renin mRNA (164), angiotensinogen 
mRNA (165), type 1 (137) and type 2 (139) angiotensin II receptor mRNA as 
discussed in Chapter 1 (Section 1.6). These findings suggest that a local renin- 
angiotensin system may exist in the human lung and this study looks for evidence of the 
component parts of the renin-angiotensin system.
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9.2 Methods
Fresh human lung was obtained from 12 patients undergoing thoracotomy for 
bronchial carcinoma Patient characteristics are shown in Table XVI. All were either 
current or ex-smokers and none were hypertensive. Normal lung tissue distant from the 
tumour margins was obtained, processed in formalin and embedded in wax for 
histological examination. A portion of the tissue was snap frozen in liquid nitrogen, 
after wrapping in silver foil to minimise trauma to the tissue, for receptor 
autoradiographic localisation and RNA extraction. This tissue was stored at -70°C until 
required for sectioning.
Table XVI Characteristics o f thoracotomy patients.
Mean (SD)
Age 66.4 (5.02) years
Sex 7 male: 5 female
FEV! 78.5 (17.7) % predicted
Smoker 6 current: 6 former
Systolic BP 133.7 (18.7) mmHg
Diastolic BP 76.1 (11.3) mmHg
9.2.1 Immunocytochemistry
Immunocytochemistry was performed on wax-embedded lung sections from 
each of twelve tissues with polyclonal antibodies to ACE and renin. Antibody binding 
was revealed using a standard alkaline phosphatase anti-alkaline phosphatase technique 
as described in Appendix 4.
9.2.2 In Situ Hybridisation
In situ hybridisation was performed to identify messenger RNA expression in 
lung tissue using digoxygenin-labelled riboprobes. Riboprobes were obtained for renin, 
angiotensinogen, ACE and AT! angiotensin II receptor. In situ hybridisation was 
performed following a standard technique with tissue binding revealed using an anti- 
digoxygenin monoclonal antibody as outlined in Appendix 6.
The renin cDNA was kindly gifted by Dr. Kevin Lynch, University of Virginia, 
U.S.A. and the ATX angiotensin II receptor cDNA by Dr. Kathleen Cumow, INSERM, 
Paris, France. The angiotensinogen cDNA was obtained commercially from the
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American Type Culture Collection, Maryland, U.S.A. The angiotensin-converting 
enzyme cDNA was gifted by Dr. Alhenc-Gelas, INSERM, Paris, France.
Riboprobes were prepared by standard techniques. The bacteria containing the 
plasmids were reconstituted and grown in broth. The DNA was extracted, the plasmid 
linearised and the desired fragment cut out by restriction digests as appropriate 
(Appendix 7).
9.2.3 Northern Blot Analysis
Frozen lung tissue from each of the twelve specimens (weight 86-350mg) and 
frozen control specimens of human and rat kidney, and human liver were homogenised 
for RNA extraction following the protocol outlined in Appendix 8. The samples were 
then run on a denaturing gel and transferred to a nylon filter. The extracted RNA was 
then probed with digoxygenin-labelled probes for ACE, renin, angiotensinogen and 
ATj angiotensin II receptor as described above. The procedures followed are set out in 
Appendix 8.
9.2.4 Angiotensin II Receptor Localisation and Autoradiography
Angiotensin II receptor localisation was performed using radiolabelled 
(sarcosine^-angiotensin II (saralasin). This technique of in situ receptor localisation has 
been developed by Dr. J.McQueen and the work described here was carried out jointly 
with him following his protocols.
Saralasin (Peninsula Laboratories) is an angiotensin II agonist which is known 
to have a higher affinity for binding to angiotensin II receptors, especially the ATX 
subtype. It is not available commercially in a radio-iodinated form and therefore 
iodination with 125I- was performed (Appendix 9).
Frozen lung tissue from each patient was then sectioned using a microtome at 
-20°C, with the sections thaw-mounted onto APES-coated slides. Sections were then 
wrapped in aluminium foil and stored at -70°C until required. Due to the technical 
difficulty in sectioning frozen lung tissue, the quality of histology obtained was sub- 
optimal. Different methods of freezing the tissue were tried but despite attempts at prior 
immersion in 5% dextrose and 10% glycerol, no improvement in histological definition 
could be obtained. Therefore straightforward snap freezing in liquid nitrogen was used.
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The frozen sections were warmed to room temperature while wrapped in foil to 
prevent further disruption to the tissue. The slides were rehydrated then the radio-ligand 
applied as described in Appendix 10.
Four sections per specimen were analysed to assess total receptor binding, non­
specific tissue binding, ATt receptor binding and AT2 receptor binding. For non­
specific binding, an excess of unlabelled angiotensin II was also added to the sections 
to competitively saturate the angiotensin II receptors, therefore any radioligand which is 
detected must represent non-specific binding outwith receptors. To demonstrate ATj 
receptor binding, the AT2 receptor antagonist PD123319 (Parke-Davis, USA) was 
added and to demonstrate AT2 receptor binding, the ATj receptor antagonist DuP 753 
(Losartan, DuPont) was added.
For film autoradiography slides were placed directly onto the film (Hyperfilm- 
3H, Amersham, UK). The Film and slides were placed in a cassette and left at -70°C for 
an exposure time of 48 hours with the use of an enhancing screen (HyperScreen, 
Amersham, UK) giving an effective length of exposure of 96 hours. The films were 
then developed by immersion in developer (Kodak D19 developer, Sigma, UK) for 6 
minutes then in fixer (Kodak GBX fixer, Sigma, UK) for 12 minutes and finally 
rinsing in water.
The autoradiographs were photographed and digitised into PC format images by 
Dr.M.McJury, Clinical Physicist, using a flatbed scanner and the Photoshop application 
on an Apple Macintosh computer. Using Metamorph image analysis software on a PC 
each individual image produced by a single tissue section was cut from the overall 
image. Manual thresholding of each image removed background pixel noise, thus 
including only pixels with silver grain deposition in the analysis. Since there were four 
images for each lung specimen, the same threshold value was used for all four images.
For each tissue section, the mean and standard deviation pixel intensity for the 
whole image was calculated, along with the thresholded area for the image and the 
percentage of the whole image represented by the thresholded region. Luminosity of 
each tissue section was calculated by multiplying the average pixel intensity (subtracted 
from 256) by the thresholded area. The results were compared statistically by ANOVA 
using Minitab.
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9.2.5 In Situ Receptor Localisation
The procedure for in situ emulsion receptor localisation is described in 
Appendix 10. Silver grains deposited over areas of receptor binding on the sections can 
be viewed by light microscopy. As well as the human lung sections, known positive 
control tissues were also examined, including rat brain, adrenal, placenta, kidney and 
rat lung.
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9.3 R esu lts
Immunocytochemistry demonstrated the presence of ACE in all 12 cases. 
Positive staining was localised to the vascular endothelium & alveolar capillaries 
(Figure 27). However, no evidence of immunoreactive renin could be found.
F igure  27 Immunocytochemistry o f human lung showing ACE in vascular 
endothelium.
i
Red staining demonstrates positivity (Arrowhead).
In situ hybridisation failed to demonstrate renin mRNA, ACE mRNA, 
angiotensinogen mRNA or AT, angiotensin II receptor mRNA in human lung tissue. 
Our laboratory technique appeared to be satisfactory as control kidney tissue showed 
renin mRNA expression in juxtaglomerular cells (Figure 28). However, due to 
technical difficulties in the preparation of the riboprobes for angiotensinogen, ACE and 
AT, receptor mRNA, it was not possible to demonstrate their efficacy on known 
positive control tissues, therefore the results for these components of the renin- 
angiotensin system are inconclusive.
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F igure 2 8 In situ hybridisation o f kidney demonstrating renin mRNA in
juxtaglomerular cells.
Counterstained with periodic acid-Schiff. Positive staining is black.
Northern blotting of homogenised frozen human lung tissue failed to 
demonstrate any evidence of renin mRNA, ACE mRNA, angiotensinogen mRNA or 
AT, angiotensin II receptor mRNA. Once again, this appears to be a true negative for 
renin mRNA, but the technical difficulties with the other riboprobes preclude any firm 
conclusions being drawn.
Angiotensin II receptor autoradiography shows angiotensin II receptors in rat 
kidney, rat brain, rat lung & human placenta (Figure 29) but no evidence of receptors in 
human lung (Figures 30). This is confirmed by luminosity measurements (Table XVII) 
in the human lung where there was no significant difference between the values for 
total, non-specific and AT, or AT2 receptor-specific binding. The small numbers of 
control rat tissues did not permit statistical analysis.
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Figure 29 Autoradiographs showing angiotensin II receptor binding in rat lung, rat
kidney, rat brain & human placenta.
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Figure 30 Autoradiograph showing angiotensin II receptor binding in human lung.
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Table XVII Luminosity values from densitometry measurement o f autoradiographs 
from human lung.
Specim en a t 2
R eceptor
AT,
R eceptor
N on-specific
B inding
Total
B inding
1 5544 12832 21518 165371
2 183779 239389 109061 317376
3 249211 264639 246690 270040
4 141355 202831 123132 174535
5 33353 49566 40860 52680
6 58993 76579 80753 79269
7 46503 33255 31105 38213
8 93441 106820 115023 58804
9 330855 552104 173055 399152
10 650999 415154 382424 460876
11 364792 206070 145548 97058
12 143051 138232 153060 153434
Mean 191823 191456 135186 188931
(SD) (185038) (161910) (101026) (142034)
In situ emulsion autoradiography fails to demonstrate angiotensin II receptors in 
significant numbers in human lung (Figure 31). However, angiotensin II receptors can 
be clearly identified over glomeruli in rat kidney control sections (Figures 32 & 33) 
confirming the efficacy of the technique.
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F igure  31 In situ emulsion autoradiography o f human lung.
Figure 32 In situ emulsion autoradiography o f kidney - low power view.
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F igure  3 3 In situ emulsion autoradiography o f kidney - high power view.
Silver grains can be seen deposited in situ over glomeruli indicating angiotensin II 
receptor binding.
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9.4 Conclusion
This study confirms the presence of ACE in human lungs and possibly 
angiotensin II ATt receptors in rat lung, but has found no evidence of renin, 
angiotensinogen nor angiotensin II receptors in human lung. Thus there does not appear 
to be a local renin-angiotensin system in the human lung.
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DISCUSSION
10.1 Activation of the Renin-Angiotensin System in Acute Severe 
Asthma
This thesis has examined several facets of the renin-angiotensin system with 
regard to its role in asthma. Further investigations on the mechanism of activation of the 
renin-angiotensin system in acute severe asthma confirms elevation of plasma renin and 
angiotensin II levels in some, but not all asthmatics. The strong correlation of plasma 
renin and angiotensin II levels suggests that the formation of angiotensin II is renin- 
dependent, presumably via the action of angiotensin-converting enzyme, but the trigger 
stimulus for activation of the renin-angiotensin system remains unknown.
10.1.1 Inflammatory Mediators
Certain inflammatory mediators were found to be elevated to varying extents in 
the group of subjects with acute severe asthma. Endothelin-1, a potent vasoconstrictor 
and bronchoconstrictor, is found in human respiratory epithelial cells (23) and 
contributes to bronchoconstriction in asthma (209). Circulating levels of endothelin-1 
are raised in some patients with acute asthma (25) but not in others (81, 210). In my 
study plasma endothelin-1 levels were raised in 16 patients (40%). The levels showed a 
trend towards a negative correlation with peak expiratory flow rate suggesting a 
possible role in bronchoconstriction.
Histamine, derived from mast cells, is involved in both the early and late allergic 
asthmatic responses (211). In this study, plasma histamine was elevated in 9 subjects 
(22.5%) and was associated with lower oxygen saturations, which may reflect either 
histamine-induced bronchospasm or an increase in histamine release due to hypoxia.
Eosinophil numbers are increased in the blood and broncho-alveolar lavage fluid 
of asthmatics and correlate with the severity of the disease (212). Eosinophilic cationic 
protein is released from activated eosinophils, is a marker of eosinophil activity and is 
elevated in serum from asthmatics providing an indicator of inflammatory airflow 
obstruction (213, 214). In this study, serum levels of ECP were elevated in 10 subjects 
(25%).
Although the levels of the above inflammatory mediators showed varying 
degrees of correlation with the severity of the asthmatic attack, there was no relationship 
with the plasma levels of renin and angiotensin II. Therefore these mediators do not 
appear to have a major role either directly or synergistically in activation of the renin- 
angiotensin system.
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The findings of this and previous work pose the question as to what purpose 
activation of the renin-angiotensin system serves in acute asthma. It is unclear whether 
this represents a pathological phenomenon, a physiological response or merely an 
epiphenomenon. In any case several potential mechanisms of activation exist:
10.1.2 Pathological Activation
The renin-angiotensin system may be activated by direct stimulation of renin 
secretion via the renal juxta-glomerular a -  and p2-adrenoceptors (187) either by p2- 
agonists, adrenaline or noradrenaline. Recently the p2-agonist salbutamol, administered 
both intravenously and by nebuliser, has been shown to cause activation of the renin- 
angiotensin system by a renin-driven, ACE-dependent mechanism (142, 143). In acute 
asthma there is a marked variation in the plasma levels of salbutamol (144) and also 
variation in the systemic absorption of nebulised salbutamol (215). In acute asthmatic 
attacks, the large doses of p2-agonists administered may reasonably be expected to 
stimulate renin release since they are in excess of doses that cause elevation of renin and 
angiotensin II (142, 143). My work confirms a wide range of plasma salbutamol levels 
which correlate with the calculated dose administered in the preceding 24 hours. 
However, there was no correlation between plasma levels of salbutamol and renin nor 
angiotensin II.
Similarly, noradrenaline, which is raised in acute asthma (39) and following 
histamine-induced bronchoconstriction (216), induces renin release in vitro, a 
mechanism that is potentiated by theophylline (217). In my study noradrenaline was 
elevated in only three cases, in contrast to previous work (39, 218) and there was no 
correlation with renin nor angiotensin II. Adrenaline was elevated in only one subject. 
Thus catecholamines having an additive or synergistic effect with salbutamol on the 
juxtaglomerular adrenoceptors to stimulate renin release is unlikely. As adrenaline is not 
elevated, the acute asthma attack and admission to hospital per se do not appear to cause 
sufficient stress to contribute to activation of the renin-angiotensin system.
The role of hypoxia in activation of the renin-angiotensin system is 
controversial: whilst it potentiates exercise-induced activation of the system (135), it 
does not directly increase renin and angiotensin II at rest (219). In acute asthma no 
correlation has been identified between either oxygen saturation or Pa02 and renin or 
angiotensin II levels.
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The strong correlation of plasma renin with plasma angiotensin II levels 
indicates that the formation of angiotensin II is renin-dependent, presumably via the 
action of angiotensin-converting enzyme. Thus formation of angiotensin II by an 
alternative pathway such as the action of non-specific proteolytic enzymes (113) is 
unlikely. Although such alternative pathways do not appear to contribute to circulating 
levels in acute asthma, this does not preclude a role at a local tissue level in the airway.
Angiotensinogen is a member of the serpin family, a group of serine protease 
inhibitors (220) and may have a role in inhibiting enzymatic action in acute 
inflammation. Angiotensinogen synthesis has been shown to increase by around 70% 
in inflammatory states such as pneumonia (111). Angiotensin II may counteract the 
vasodilation that accompanies fever and sepsis (111). Plasma levels of angiotensinogen 
are also increased by oral oestrogens, hypophyseal adreno-corticotrophic hormone and 
glucocorticoids (221), the latter effect probably due to mineralocorticoid activity (222).
Asthma is now treated routinely with inhaled corticosteroids and both oral and 
intravenous corticosteroids are administered in acute exacerbations. This could result in 
further elevation of angiotensinogen levels. Unfortunately in this study it was not 
possible to measure plasma angiotensinogen, but there was no correlation between the 
administered corticosteroid dose and plasma renin or angiotensin II levels. It would be 
interesting to look further at plasma angiotensinogen and angiotensin II levels in 
asthma. In addition, measurement of oestrogen and angiotensinogen levels in female 
asthmatics who have pre-menstrual worsening of their symptoms would be of interest, 
particularly in the light of concerns being raised over the apparent increased risk of 
developing late-onset asthma through the administration of oestrogens as hormone 
replacement therapy (223).
10.1.3 Physiological Activation
Elevation of mean systolic blood pressure occurs in acute asthma (39). The 
absence of raised blood pressure in those asthmatics with elevation of renin and 
angiotensin II levels is therefore surprising. The release of renin and subsequent 
angiotensin II formation in acute asthma may be part of a physiologic homeostatic 
regulatory mechanism to maintain an adequate blood pressure in the face of arterial 
vasodilatation. Indeed this role for the renin-angiotensin system has been postulated in 
acute inflammatory conditions (111). Histamine has vasodilator properties (21) but 
blood levels did not correlate with renin or angiotensin II levels. Bradykinin is also a 
potent bronchoconstrictor and also causes arterial vasodilation and capillary leakage 
(224). Plasma kinin is elevated in acute asthma and has been found in bronchoalveolar
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lavage fluid from asthmatics following allergen challenge (225). Therefore bradykinin- 
induced vasodilation could trigger activation of the renin-angiotensin system, however 
bradykinin levels have not been estimated in this study.
The renin-angiotensin system is also activated by a drop in renal perfusion 
pressure, either a local reduction in renal artery flow or a reduction in systemic blood 
pressure. In acute severe asthma, raised intra-thoracic pressure produces mechanical 
impairment of cardiac diastolic ventricular filling {pulsus paradoxus) leading to an 
intermittent drop in systemic blood pressure which could stimulate the renin-angiotensin 
system. The levels of urea and creatinine measured in the asthmatic subjects were 
normal making a chronic disturbance of renal function unlikely but no inferences can be 
made about acute changes in renal function.
Electrolyte imbalance, in particular hyperkalaemia, can stimulate renin release. 
Administration of salbutamol is known to cause a shift of potassium ions intracellularly 
resulting in hypokalaemia (226) and thus would antagonise renin release. However, 
sodium and potassium levels were normal in the study subjects.
It still remains unclear what role the renin-angiotensin system is serving in acute 
asthma although the administration of salbutamol may in part stimulate renin release. 
The absence of a rise in blood pressure suggests that angiotensin II may be playing a 
compensatory role in maintaining blood pressure in the face of vasodilation induced by 
the inflammation in acute asthma.
10.2 The ACE Gene Insertion/Deletion Polymorphism in Asthma
There is variation in serum ACE activity as the result of an insertion/deletion 
polymorphism of the ACE gene (169). Given the elevation of plasma angiotensin II and 
renin in some acute asthmatics but the lack of any association with serum ACE activity 
the role of the ACE genotype in asthma was studied. Individuals who are homozygous 
for the deletion polymorphism have a higher serum ACE activity (169) and 
subsequently the ability to generate greater amounts of angiotensin II from angiotensin I 
(172). This could potentially explain the elevation of angiotensin II in some asthmatics 
but would not account for elevation of renin levels.
In studies of ACE genotyping using the two-primer method of Rigat et al. 
(193), polymerase chain reaction has on occasion failed to amplify the insertion allele in 
heterozygotes. This can lead to overestimation of the DD homozygote. However, the 
three-primer method of Evans et al. (174) increases the accuracy of detection of the
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insertion. In this study both methods have been employed and the ACE genotype was 
confirmed in all cases with both methods.
My results confirm that the highest ACE activity in both the asthmatic and 
control groups was associated with the deletion homozygote, the lowest ACE activity 
with the insertion homozygote and the heterozygote intermediate. In the asthmatic 
subjects there was an excess of the deletion allele when compared to the control 
population however this did not reach statistical significance. This finding is supported 
by a recent study by Benessiano et al. (227) which found a higher frequency of the 
deletion homozygote genotype in a group of asthmatics compared to non-asthmatic 
controls.
Although there may be an association between the ACE deletion allele and 
asthma it is difficult to implicate this in the aetiology of asthma. Benessiano was unable 
to demonstrate any association between ACE genotype and pulmonary function (227). 
Costerousse (170) showed that ACE is expressed in human T lymphocytes and 
monocytes and, although making little contribution to circulating ACE, it contribute to 
local tissue levels. T lymphocytes accumulate at sites of inflammation and angiotensin II 
is chemotacticforT cells. Bradykinin and substance P are also involved in lymphocyte 
proliferation, neutrophil chemotaxis, phagocytosis and mediator release, therefore T 
lymphocyte ACE may act as a regulatory mechanism to metabolise bradykinin produced 
locally during tissue inflammation. As a consequence of this, increased amounts of 
angiotensin II could be produced locally.
Lung tissue ACE activity has not been studied in asthmatics although it is well 
known that the pulmonary capillaries are the richest source of ACE as a consequence of 
the size of the capillary bed. It would be interesting to compare asthmatic lung 
specimens with those of non-asthmatic controls to investigate whether the inflammatory 
response in asthma has any effect on lung tissue ACE activity.
Serum ACE activity is elevated in other pulmonary diseases, in particular 
sarcoidosis. This is due to activation of the monocyte-macrophage system forming 
granulomas (228). In vitro, monocytes increase ACE expression during differentiation 
to macrophages (170). Serum ACE is also elevated to varying degrees in many other 
diseases including tuberculosis, thyrotoxicosis, diabetes mellitus, silicosis, leprosy and 
alcoholic liver disease (228). Although not sufficiently specific to be used as a 
diagnostic tool in sarcoidosis, serum ACE activity is a useful index for monitoring 
disease activity.
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It is known that ACE activity is suppressed by corticosteroids in both healthy 
individuals and those with lung disease including asthmatics (229). However, no 
association was found between ACE activity and steroid dose in this study. Combined 
oestrogen and progestogen hormone replacement therapy also reduces serum ACE 
activity in post-menopausal women by 20% over 6 months and ACE activity also falls 
during pregnancy (230). Not surprisingly, ACE activity also falls during treatment with 
ACE inhibitors (228).
A troublesome side-effect of ACE inhibitors is cough, which is attributed to 
increased bradykinin, but cough does not occur in all those treated. Furuya et al. (231) 
demonstrated that those with ACE inhibitor-induced cough had an increased frequency 
of the insertion allele and the II homozygote genotype with consequently the lowest 
baseline ACE activity. This appears to increase susceptibility to ACE inhibitor-induced 
cough. Given the effect of angiotensin II on bronchial reactivity it would be reasonable 
to suggest that ACE inhibitors may also have an effect on the airways, however this 
area remains controversial. In one series of patients with ACE inhibitor-induced cough 
enalapril increased bronchial reactivity to histamine (232). Another series of subjects 
with ACE inhibitor-induced cough found a lower histamine PC20 than controls on ACE 
inhibitors with no cough, suggesting this may be due to bradykinin (233). However, a 
further study of hypertensive asthmatics demonstrated that treatment with captopril had 
no effect on FEVX or bronchial reactivity to methacholine (234). Therefore if ACE 
inhibitors have any effect on the airways it appears to be relatively minor and of 
doubtful clinical significance.
Polymorphisms of the other components of the renin-angiotensin system, in 
particular the angiotensinogen gene (183), which is the rate-limiting element in the 
system, could affect angiotensin II levels. Therefore, if a sub-group of asthmatics had 
the propensity to produce higher amounts of angiotensinogen, that, in combination with 
other stimuli such as exogenous p2-agonists could theoretically lead to the production of 
higher levels of angiotensin II for a given increase in renin release.
A further unexpected finding was the variation in ACE activity for a given 
genotype between acute medical hospital admissions and normal controls. When the 
data from the asthmatic subjects and a group of non-asthmatic acute medical hospital 
admissions were combined, the serum ACE activities for the DD and ID genotypes 
were higher than for the equivalent genotypes in the control population. Despite this, 
there was no difference in the allele frequency or genotype distribution between the two 
groups. This difference was not evident when comparing the asthmatic subjects alone
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and may therefore simply be a consequence of the relatively small study numbers. In 
addition, the control population was younger than the hospital in-patient group and thus 
the difference seen may be an age effect. The stress of hospital admission may increase 
ACE activity but no association was found with circulating catecholamine levels. 
Indeed, the majority of the asthmatics received treatment with corticosteroids which are 
known to suppress ACE activity (228). Thus there appear to be other factors involved 
in determining ACE activity than simply ACE genotype. It is also possible that 
individuals with a given genotype who have the capacity to produce a higher ACE 
activity may be more susceptible to medical illness.
10.3 The Effect of Angiotensin II on Histamine-Induced 
Bronchoconstriction
Angiotensin II has weak bronchoconstrictor properties (132) but also has the 
capacity to potentiate the bronchoconstrictor effects of the mediators methacholine (in 
vivo and in vitro) (141) and endothelin-1 (in vitro) (26). These effects appear to be 
mediated by the ATX angiotensin II receptor subtype (26). The effect of angiotensin II 
on other mediators of bronchoconstriction is hitherto unknown and thus histamine- 
induced bronchoconstriction has been examined. However, the results show that 
angiotensin II does not affect histamine-induced bronchoconstriction in human bronchi 
either in vitro or in vivo.
In vivo, intravenous infusion of angiotensin II results in an elevation of plasma 
angiotensin II to a maximum of median (inter-quartile range) 43.9 (36.9-52.4) pg/ml 
compared to maximum levels measured by Millar et al. (132) in asthmatic patients of 56 
(12-109) pg/ml and levels of 10.9 (4.3-23.5) pg/ml in the current study during acute 
severe asthma. Therefore, the levels achieved by the infusion of angiotensin II are 
physiologically relevant.
The rise in systolic and diastolic blood pressure during the 1 and 2 ng/kg/min. 
angiotensin II infusions confirms its physiological effect. The plasma levels of 
angiotensin II measured during this study were similar to those found in the previous 
study by M illard  al. (141) where angiotensin II potentiated methacholine-induced 
bronchoconstriction.
As there was no significant effect on spirometry following 30 minutes of the 
infusion on each study day it can be concluded that the dose of angiotensin II 
administered did not cause bronchoconstriction.
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The reason for angiotensin II potentiating methacholine- (141) but not 
histamine-induced bronchoconstriction is undoubtedly complex and may be multi­
factorial. The two studies have heterogeneous groups of subjects although four subjects 
took partin both studies. The current study group were older [mean (SD) age 41 (5.3) 
years compared to 27 (8) years in the study by Millar et al. (141)], but both groups 
were mild asthmatics with mean (SD) FEVj 88 (11)% predicted in the current study and 
82 (9)% predicted in the study by Millar etal.( 141). Bronchial reactivity during placebo 
infusion was similar in both groups with geometric mean (range) PC20 histamine 2.67 
(0.89-9.57) mg/ml in the current study and PC20 methacholine 3.09 (1.15-6.0) mg/ml 
in the study by Millar et al. (141). Therefore it is unlikely that variation in patient 
selection between these two studies accounts for the different effect of angiotensin II on 
histamine- and methacholine-induced bronchoconstriction in vivo.
The severity of asthma may be important: In asthmatics with greater bronchial 
reactivity the effect of angiotensin II on histamine-induced bronchoconstriction may be 
different due to greater local inflammation, the presence of higher levels of mediators or 
an increased volume of airway smooth muscle. However, it is established that in mild 
asthma angiotensin II can potentiate the effect of methacholine and thus there appears to 
be a fundamental difference between the interaction of angiotensin II with methacholine 
and histamine.
10.3.1 Receptors
In the human airway the lack of interaction between angiotensin II and 
histamine could be explained by the absence of functional angiotensin II receptors. 
Although there is no direct evidence of tissue-specific angiotensin II receptors in the 
lungs, Cumow etal. (137) have extracted type-1 angiotensin II (ATX) receptor mRNA 
from human lung tissue. Both ATt (167) and AT2 (139) angiotensin II receptor mRNA 
have also been identified in fetal rat lung.
In vitro, studies of reactivity in bovine bronchial rings have shown an ATt 
receptor-mediated potentiating effect of angiotensin II on endothelin-1 evoked 
bronchoconstriction (26). Although the mild bronchoconstrictor effect of angiotensin II 
in asthmatic airways in vivo (132) and its potentiating effect on methacholine-induced 
bronchoconstriction (141) are not proven to be receptor-specific phenomena, it is likely 
that functional angiotensin II receptors exist in the human airway.
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A further potential site of interaction is at the receptor itself. Angiotensin II 
uncovers previously silent a 2-adrenoceptors in the rabbit distal saphenous artery (196) 
and if a similar interaction occurred with receptors for spasmogens in airway smooth 
muscle this could lead to potentiation.
10.3.2 Second Messengers
The lack of potentiation with angiotensin II and histamine may be due to 
different intracellular second messenger pathways and varied cross-talk between 
pathways. In vascular tissue, the type 1 angiotensin II receptor is coupled to a G- 
protein activating phospholipase-C, liberating diacyl-glycerol (DAG) and inositol- 
triphosphate (IP3) thereby causing a rise in intracellular calcium (235). In some tissues, 
the angiotensin II receptor is also coupled to an inhibitory G-protein which inhibits 
adenylate cyclase (236). Studies also suggest that angiotensin II may be able to act 
directly within cell nuclei, possibly reaching the cell nucleus by receptor-mediated 
endocytosis (131, 237). This could circumvent second messenger pathways. However, 
the effect of angiotensin II on intracellular pathways in airway smooth muscle remains 
to be characterised.
Histamine acts on airway smooth muscle via the Hi receptor which is also 
coupled to a G-protein activating phospholipase C and liberating DAG and IP3 (20). 
The increase in IP3 is inhibited by cyclic adenosine-monophosphate (cAMP), which 
attenuates the histamine-induced increase in intracellular calcium in canine airway 
smooth muscle (20). Histamine also exerts some of its effects by reflex 
bronchoconstriction through activation of cough receptors in the larynx and trachea 
(22).
Cholinergic muscarinic receptors in the airways are also coupled to membrane 
phospholipid hydrolysis to form IP3 but this occurs by a different pathway which is 
insensitive to cAMP (20).
Therefore the second messenger pathways for histamine and acetylcholine 
/methacholine are subject to different modulatory influences and cross-talk with 
angiotensin II second messenger pathways intracellularly could have different end 
results.
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10.3.3 Innervation
The most likely explanation for the different effect of angiotensin II on the 
actions of histamine and methacholine is the role of parasympathetic ganglion cells. 
Angiotensin II acts pre-synaptically on cholinergic neurones inducing the release of 
acetylcholine (44); when combined with the administration of nebulised methacholine, 
this would result in a greater degree of bronchoconstriction. Angiotensin II also 
enhances the responses of tissues to sympathetic nerve stimulation and exogenous 
adrenoceptor agonists by several mechanisms: i) activating pre-junctional angiotensin II 
receptors which facilitate noradrenaline release, ii) preventing noradrenaline reuptake by 
the nerve terminal, iii) increasing the synthesis of noradrenaline and iv) enhancing the 
response of effector cells to noradrenaline (197).
Mast cells are found around parasympathetic ganglion cells in the guinea pig 
airway and degranulate following antigen exposure releasing histamine and other 
preformed mediators locally. Following both antigen challenge and the direct 
administration of histamine, enhanced excitability occurs in guinea pig bronchial 
ganglion neurones (43). Therefore, if histamine is already having a direct effect on 
presynaptic cholinergic ganglion cells then it is unlikely that angiotensin II could 
enhance this significantly via the release of further acetyl choline.
This is undoubtedly an over-simplification of the complex process occurring 
within these ganglia in the airway wall. These neurones are subject to many different 
modulations of their activity by both facilitatory and inhibitory influences (22). Many 
pre-ganglionic axons converge on parasympathetic ganglion neurones which may 
require the input of many sub-threshold stimuli to elicit a post-ganglionic effect (238).
Thus there are several ways to explain the difference between the effects of 
angiotensin II on methacholine and histamine in human airways. It will be interesting to 
assess the effect of angiotensin II on endothelin-1-induced bronchoconstriction in the 
human airway in future studies.
10.4 Angiotensin II as a Growth Promoter in Airway Rem odelling
In chronic asthma, airway remodelling causes changes in the epithelium, 
basement membrane, mucous glands, smooth muscle and connective tissue (48). The 
two most important functional changes are first, increased airway smooth muscle which 
amplifies the effects of bronchoconstrictor stimuli (54) and secondly, thickening of the 
adventitia which uncouples the airway from the elastic recoil forces of the surrounding 
lung parenchyma (68).
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Many growth promoters contribute to airway remodelling (73, 201) and these 
are listed in Table I. In some cases, these agents have a synergistic effect on airway 
smooth muscle cells (32). Recent in vitro work shows that angiotensin II to be a growth 
promoter for human airway smooth muscle cells (101).
Angiotensin II is an important growth promoter in cardiovascular remodelling. 
It increases DNA synthesis in arteries both by raising blood pressure and by a direct 
effect on the arterial wall independent of blood pressure (154). There are many parallels 
between the structural changes in the vasculature and in the airways although the 
physiology of the two systems is quite different.
The work in Chapters 7 and 8 examining the structural changes in the rat airway 
and the systemic vasculature has manipulated the renin-angiotensin system by different 
means. In the first study, a two week infusion of angiotensin II increased circulating 
angiotensin II. In the second study, dietary sodium restriction was used to cause 
endogenous stimulation of the renin-angiotensin system through systemic sodium 
depletion.
In the first study a two week infusion of angiotensin II causes a significant rise 
in blood pressure and suppresses renin mRNA expression and presumably renin 
synthesis in the juxtaglomerular apparatus of the kidney. This confirms the findings of 
previous studies in rats where infused angiotensin II caused a 45% reduction in renin 
mRNA expression in the kidneys (110). The animals infused with angiotensin II had 
significantly higher BrdU indices in arteries and although the arteries tended to be 
thicker in the angiotensin II group, there was no significant difference in geometry of 
the mesenteric arteries and veins between the two groups. These findings are in keeping 
with previous angiotensin II infusion studies (150, 186). The absence of a rise in 
plasma angiotensin II at the end of the infusion may reflect homeostatic compensatory 
reduction in endogenous angiotensin II formation.
In the airway, there was no difference in either the BrdU indices or the volume 
of the epithelium, airway smooth muscle and adventitia in the control and angiotensin II 
infused animals.
In the second study sodium depletion caused minor, insignificant variations in 
blood pressure, with elevation of plasma renin activity and aldosterone confirming 
activation of the renin-angiotensin system. Kidney renin mRNA expression increased, 
confirming the findings of previous sodium depletion studies where renal
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angiotensinogen mRNA was also increased (239). A separate study by McEwen et al. 
(186) has examined the mesenteric vasculature from these animals and found a 
significant increase in DNA synthesis in the arterial media of the sodium-depleted 
group.
By contrast, in the airways sodium depletion had no effect on DNA synthesis in 
the epithelium, airway smooth muscle or adventitia and no morphometric changes were 
found in the volume of these three tissues.
The lack of increased DNA synthesis in the airways makes hyperplasia and 
hypertrophy unlikely. This is supported by the lack of morphometric changes. Thus 
there is no evidence of remodelling in the rat airway in response to systemically infused 
angiotensin II or to endogenous activation of the renin-angiotensin system by dietary 
sodium restriction despite changes in the vasculature.
There are several possible reasons for the discrepancy between the effects of 
angiotensin II on arteries and airways. First, it is well established that angiotensin II is a 
growth promoter in the vasculature (152), the heart (145) and the kidneys (146). This 
effect is mediated primarily by ATt angiotensin II receptors (240) and although these 
receptors are present in arteries (131) their existence has yet to be confirmed in the 
airways. ATj receptor mRNA has been isolated from human (137) and rat (136) lung, 
however, my histological studies of human lung tissue (Chapter 9) have failed to 
demonstrate angiotensin II receptors in situ although they may be present in rat lung. 
Wharton et al. (241) have presented contrasting evidence which demonstrates AT2 
receptors in human fetal lung and both ATt and AT2 receptors in human adult lung 
using similar techniques.
In vitro, angiotensin II potentiates endothelin-1-evoked bovine
bronchoconstriction by an ATX receptor-mediated effect (26). This provides indirect 
evidence for the existence of functional angiotensin II receptors in bovine airways, but 
there may be species variation in the number and distribution of angiotensin II 
receptors.
Angiotensin II receptor expression is regulated both by changes in sodium 
homeostasis and by the renin-angiotensin system. In sodium deficiency, angiotensin II 
receptors increase in the adrenal zona glomerulosa and decrease in the vasculature, renal 
glomeruli, platelets, uterine and bladder smooth muscle. These changes appear to be 
related to raised circulating angiotensin II levels and can be reproduced by angiotensin 
II infusion and reversed by administration of an ACE inhibitor. Uterine angiotensin II
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receptors are also modulated by oestrogen levels. Brain angiotensin II receptors are not 
affected by changes in either circulating or local angiotensin II levels. Angiotensin II 
receptors in the anterior pituitary are reduced by chronic oestradiol administration but 
are not affected by angiotensin II infusion or sodium balance (131). Glucorticoids 
potentiate the vasoconstrictor action of angiotensin II by increasing angiotensin II 
receptor numbers (242).
Thus, in both of the studies manipulating the renin-angiotensin system there will 
be down-regulation of angiotensin II receptors in the vasculature. The regulation of 
angiotensin II receptors in the lungs is not known, but is likely to follow that of 
receptors in other tissues and therefore may be down-regulated. Despite down- 
regulation of angiotensin II receptors in the vasculature, increased DNA synthesis still 
occurs, so down-regulation per se is not sufficient to prevent the mitogenic effect of 
angiotensin II. However, if the initial receptor density were lower in the lungs than in 
the vasculature, a further reduction in receptor numbers may be sufficient to fall beneath 
a threshold level whereby angiotensin II may not exert proliferative effects.
Secondly, systemic infusion of angiotensin II causes changes in the vasculature, 
but concentrations of angiotensin II reached in other tissues are not known. Local 
angiotensin II levels in the airway may not reach threshold concentrations for induction 
of cell growth. However, certain inflammatory proteases can cleave angiotensinogen to 
form angiotensin II (118) and could feasibly produce higher tissue levels in the 
presence of inflammation.
Thirdly, although angiotensin II promotes growth, other mediators have anti­
proliferative properties and antagonise its effects. In the arterial wall TGF-Pj secreted 
by endothelium antagonises the effect of angiotensin II on medial smooth muscle (152). 
This inhibition is removed by endothelial damage. Bronchial epithelium also 
synthesises TGF-p! (153) thus epithelial damage and shedding that occur in asthmatic 
airways could facilitate growth promotion by angiotensin II through removing an 
important inhibitor. Conversely, the absence of structural changes in the rat airway in 
these studies could reflect the presence of compensatory anti-proliferative stimuli in an 
intact epithelium. The AT2 angiotensin II receptor subtype has an anti-proliferative 
effects in some tissues (138) and if predominant in rat airways, would result in a net 
negative effect of angiotensin II on cell growth.
Angiotensin II has synergistic properties potentiating some bronchoconstrictors 
(26, 141) but not others (Chapters 5 and 6). In asthma, inflammation with capillary
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leakage results in the presence of many different inflammatory mediators which could 
act synergistically to cause airway cell growth and bronchoconstriction. As airway 
remodelling is probably the end result of a combination of many growth promoters and 
inhibitors, any effect of angiotensin II on other modulators of cell growth could alter the 
final outcome even if angiotensin II itself has no proliferative effect. Thus, the absence 
of airway inflammation in both studies may be masking a potential growth promoter 
effect of angiotensin II if co-mitogens were present. A suitable model of airway 
inflammation would be required to test this point further.
Finally, although angiotensin II promotes growth of human airway smooth 
muscle in vitro, my results may simply indicate that angiotensin II infusion has no 
effect on cell growth in the normal rat airway in vivo.
In summary, neither a two week infusion of angiotensin II sufficient to cause an 
elevation of blood pressure nor a two week period of dietary sodium restriction, both of 
which are sufficient to increase DNA synthesis in the mesenteric arteries, cause 
significant airway remodelling in the rat. Further in vivo manipulations of the renin- 
angiotensin system in a suitable model of airway inflammation are required to Firmly 
establish or refute the role of angiotensin II in airway remodelling in asthma.
10.5 Is There a Local Renin-Angiotensin System in the Lungs?
The renin-angiotensin system involves several organs including the liver, 
kidneys, lungs, vasculature and adrenal glands. However, local renin-angiotensin 
systems have been identified in many organs and tissues as reviewed in the Introduction 
(Section 1.6). Circumstantial evidence from many existing studies would support the 
existence of a local renin-angiotensin system within the lungs but hitherto no studies 
have examined this directly.
To prove the existence of a local renin-angiotensin system it is necessary to 
demonstrate the presence of the components, namely angiotensinogen, renin, ACE and 
functional angiotensin II receptors in lung tissue. Histological techniques can be used to 
identify peptides and enzymes directly by applying specific, labelled antibodies by 
immunocytochemistry. Using this method my results confirm the presence of ACE 
distributed in pulmonary capillaries and on vascular endothelium. Antibodies for renin 
failed to demonstrate any evidence of this.
More sensitive molecular biological techniques can be used to identify the 
presence of messenger RNA which gives the tissues the ability to transcribe the
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peptides and enzymes being studied. In situ hybridisation allows this to be performed 
on tissue sections permitting histological identification of the positive cell or tissue 
types. However, using labelled riboprobes for angiotensinogen, ACE, renin and the 
ATj angiotensin II receptor, no evidence of these was found in human lung tissue.
Finally, homogenised lung tissue was examined by Northern Blot analysis to 
look for the presence of mRNA fragments but again no evidence of the components of 
the renin-angiotensin system was found. Given these negative results it was decided not 
to proceed to polymerase chain reaction, the most sensitive investigation available.
The search for angiotensin II receptors with autoradiographic film and in situ 
techniques failed to demonstrate receptors in human lung, although films suggested the 
presence of AT1 receptors in rat lung. This may be due to species differences in receptor 
numbers and expression. However, this may also be a consequence of infiltration by 
inflammatory cells as many of the rat lung specimens showed histological evidence of 
pulmonary infection, a common problem in animal houses.
I found no evidence of any of the components of the renin-angiotensin system 
in human lung apart from ACE which is well known to be present in pulmonary 
capillaries. The renin riboprobe was technically satisfactory as shown by the strongly 
positive control thus supporting the negative findings in human lung as a true negative 
for renin mRNA. These negative findings for the other components may also be a 
consequence of inadequacies in our molecular techniques as difficulties with the 
riboprobes led to failure on positive control tissues with the probes for 
angiotensinogen, ACE and the ATj receptor. In addition, low levels of tissue 
expression of these components may be undetectable by the sensitivity of the techniques 
employed.
The existing evidence for the presence of the components of the renin- 
angiotensin system in the lungs is mainly circumstantial from various studies in both rat 
and human tissue. ACE is undeniably present (158, 159). Although renin has been 
demonstrated immunocytochemically in human lung this has only been in pathological 
conditions such as bronchial carcinoma of different histological types (161, 162). It is 
possible that renin is taken up from the circulation by cells in these pulmonary lesions 
and stored in lysosomes rather than being synthesised within the lungs (243). Renin 
mRNA has been found in normal rat lung (164) but there are no reports in normal 
human lung. A case-report describes the presence of renin mRNA localised to tumour 
cells in a pulmonary metastasis from an epithelioid soft tissue sarcoma but there was no 
evidence of positive cells in the unaffected human lung tissue (163). Angiotensinogen
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mRNA has been identified in rat lung (165) but there are no reports in human lung. The 
results of my work are in accord with these findings.
Angiotensin II receptor mRNA, both ATj (136, 166), predominantly the AT1a 
subtype (167, 168), and AT2 (139) has been identified in normal rat lung. Cumow et al. 
(137) have identified ATx mRNA in normal human lung where it is expressed in similar 
amounts to the kidneys and testes. Since the completion of the work of this thesis 
another group using a similar technique with radio-labelled angiotensin II have 
demonstrated the presence of angiotensin II receptors in normal fetal and adult human 
lung (241). In fetal lung the AT2 subtype was predominant and localised to the bronchi 
while the A I\ subtype was present in lower density in the mesenchyme. In adult lung 
receptors were found in the vasculature (mainly AI\) and parenchyma (both ATX and 
AT2). Alveolar cells expressed AT2 receptors but no comment was made about 
bronchial smooth muscle.
The failure to demonstrate angiotensin II receptors in my human lung specimens 
does not appear to be a technical problem as both subtypes of receptors are clearly 
demonstrated in several control tissues. Collection and processing procedures were 
identical for both lung and control tissues however, frozen lung proved more difficult to 
section. All the human lung specimens were obtained from cigarette smokers with 
bronchial carcinoma and it is possible that exposure to cigarette smoke or factors 
released from the tumour cells may cause down-regulation of receptor expression.
In summary, although there is some doubt whether the lungs possess all 
components of a local renin-angiotensin system, they play an important role in the 
systemic renin-angiotensin system through the actions of pulmonary ACE. The lungs 
appear to be another target organ for the renin-angiotensin system. AT2 receptors may 
play a role in fetal development (139) and thus may be involved in the regulation of fetal 
lung development. In addition, functional angiotensin II receptors respond to circulating 
angiotensin II by bronchoconstriction (132). However the physiological relevance of 
this remains uncertain. It is possible that some components of the renin-angiotensin 
system may be present in small amounts below our limits of detection or may interact 
with the circulating renin-angiotensin system. Active inflammation within the lungs may 
be required to “switch on” the production of components locally, for example it is 
known that inflammatory proteases can produce angiotensin II from angiotensinogen 
(113) and angiotensin I (120).
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11. CONCLUSION
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11.1 Conclusion
The work described in this thesis has examined the role of the renin-angiotensin 
system in asthma. Elevation of plasma renin and angiotensin II levels was again 
demonstrated in some asthmatics during episodes of acute severe asthma. Despite an 
extensive evaluation of clinical features, circulating peptides, inflammatory mediators 
and catecholamines no correlation was found. In particular, plasma salbutamol levels, 
despite administration in high doses, showed no relation with either plasma renin or 
angiotensin II levels. Various mechanisms of activation have been discussed but my 
results do not implicate any single factor. The many inflammatory mediators and 
cytokines released during acute attacks of asthma, as well as exogenously administered 
medications could interact synergistically to activate the system, but no evidence has 
been found to support this.
Although serum ACE activity did not correlate with plasma renin or angiotensin 
II levels, a higher ACE activity was associated with the deletion homozygote than the 
heterozygote and insertion homozygote. In addition, there was a trend for the deletion 
allele to be present in a higher frequency than expected in the group of acute asthmatics. 
This finding needs further evaluation to determine its clinical relevance.
Although angiotensin II can potentiate the effects of other bronchoconstrictors 
such as methacholine and endothelin-1, it has no effect on histamine-induced 
bronchoconstriction either in vitro or in vivo. The possible reasons for this have been 
discussed already (Section 10.3). It will be interesting to see the results from future 
studies examining the interaction of angiotensin II with other mediators such as 
endothelin-1 and leukotrienes in human airways.
Despite angiotensin II being a likely candidate as a growth promoter for airway 
smooth muscle and airway remodelling, infusion of angiotensin II into rats over a two- 
week period and endogenous activation of the renin-angiotensin system by dietary 
sodium restriction had no effect on DNA synthesis or airway morphometry. However, 
DNA synthesis increased in the mesenteric arteries in both these cases. This may 
represent a species-specific effect as angiotensin II has mitogenic properties on human 
airway smooth muscle cells in vitro (101).
Immunohistochemical examination of human lung tissue has confirmed the 
presence of ACE in pulmonary capillary vascular endothelium but neither renin, 
angiotensinogen nor type 1 or type 2 angiotensin II receptors were found. Angiotensin 
II receptor labelling did however appear to demonstrate angiotensin II receptors in rat 
lung, but further evaluation is required to confirm this and to localise the receptors to
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particular cell types. My work has failed to confirm the findings of Wharton et al. (241) 
who demonstrated angiotensin II receptors in both fetal and adult human lung using 
similar techniques. Circumstantial evidence as discussed previously makes the presence 
of functional angiotensin II receptors in human lungs likely.
The clinical relevance of the renin-angiotensin system’s involvement in asthma 
is of questionable significance. Although the lungs are organs which are intimately part 
of and respond to the renin-angiotensin system they do not appear to possess the 
components necessary to comprise a local system.
The fall in FEVj in response to infused angiotensin II is only 12% (132) which 
is a marginal change in airway calibre in normal lungs but may be more significant if 
occurring in airways which are already narrowed. This fall is also much less than other 
bronchoconstrictors of known clinical relevance such as histamine and acetylcholine. 
Therefore angiotensin II has at best only a minor role in bronchoconstriction occurring 
in clinical situations in the presence of other more potent spasmogens. The synergistic 
effects of angiotensin II are of more interest and may be of more clinical relevance 
particularly in acute severe asthma. However, these synergistic effects vary among 
different bronchoconstrictors.
If angiotensin II is shown to have mitogenic effects on airway smooth muscle in 
human lung it will join the growing list of substances identified as growth promoters in 
airway remodelling (73). This is a relatively recent concept which explains the 
irreversible component to airflow obstruction found in some chronic asthmatics. These 
growth promoters remain to be ranked by their relative potency to allow targeting of 
specific agents for therapeutic intervention, however it is currently believed that inhaled 
corticosteroids commenced early in the course of the disease may help to prevent 
structural changes.
The current state of knowledge regarding the renin-angiotensin system and 
asthma is summarised in Figure 34.
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Figure 34 The current role o f the renin-angiotensin system in asthma.
Local RAS in Lung
- ACE in pulmonary 
capillaries.
- ATj mRNA isolated.
- Probable functional AT\ 
receptors.
- ?AT2 receptors on alveolar 
epithelial cells.
- No evidence of renin.
- ?Angiotensinogen present.
Airway Remodelling
- Ang.II stimulates growth 
of human airway smooth 
muscle cells in vitro.
- No effect on rat airway 
in vivo.
ACE Genotype
- Possible increased 
frequency of D allele 
in asthmatics.
- Higher ACE activity in 
DD homozygotes.
Acute Severe Asthma
- Subgroup with elevated 
plasma renin & ang.II.
RENIN-ANGIOTENSIN
SYSTEM
Bronchoconstriction
- Ang.II alone is a weak 
bronchoconstrictor.
- Ang.II enhances effects of 
methacholine, endothelin-1 
but not histamine.
P- A gonists
- Increase plasma renin & 
ang. II levels.
- Blocked by ACEI.
- No correlation found in 
acute asthma.
Key: Ang.II: angiotensin II; ACE: angiotensin-converting enzyme; ACEI: ACE
inhibitor; RAS: renin-angiotensin system; AT^ type 1 angiotensin II receptor; AT2: type 
2 angiotensin II receptor; D: deletion allele.
The renin-angiotensin system does appear to have a minor involvement in 
asthma with a borderline clinical relevance in some asthmatics. It is unlikely to have a 
major role in chronic or stable asthma and the evidence currently available for its 
effects, if any, in acute severe asthma is not sufficient to warrant trials of therapeutic 
intervention with drugs such as ACE inhibitors and angiotensin II receptor antagonists. 
However, the elevation of plasma renin and angiotensin II should be borne in mind in 
the future as the results of further studies on the pathogenesis of asthma become 
available.
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12. LIMITATIONS OF THE WORK OF THE THESIS
132
12.1 Clinical Studies
The numbers of patients recruited into the acute asthma study were relatively 
small given that only a sub-group had activation of the renin-angiotensin system and 
although the results obtained were unequivocally negative it may be possible that a 
minor association could have been missed.
The study of ACE genotype in asthmatics has demonstrated a trend towards a 
higher than expected frequency of the deletion allele however, this did not reach 
statistical significance. It is possible that if a larger number of asthmatics were studied 
this may reveal a significant difference.
12.2 In  Vitro Studies
The studies investigating the effect of angiotensin II and sodium depletion on 
remodelling of the rat airway are limited by the fact that although angiotensin II is raised 
in asthma, in the rat airways studied there was no underlying inflammation as would be 
found in asthmatics. Furthermore, it is not clear if rat airway smooth muscle is 
responsive to angiotensin II and in vitro cell culture studies may be useful to clarify 
this.
The human lung specimens obtained for the study were unfortunately not from 
normal, healthy volunteers but from patients undergoing thoracotomy and lung 
resections for bronchial carcinomas, all of whom were smokers. Therefore the lung 
tissue used was “normal” lung from the resected tissue taken as far from the tumour 
margins as possible. However it is not possible to exclude an effect caused by a field 
change induced by exposure to tobacco smoke or the effects of tumour factors released 
locally.
In addition, time limitations and technical problems with riboprobe preparation 
prevented the histological section of the thesis from being more comprehensive. Despite 
this valuable experience was gained in the molecular techniques outlined in Chapter 9.
Although the autoradiographs obtained from the rat lung tissues appear to show 
evidence of ATj receptors, it was not possible to localise these histologically. A 
problem encountered with the laboratory animals used was that of pulmonary infections 
which are common in animal houses. It is possible that the receptor binding 
demonstrated may be a consequence of an inflammatory cell infiltrate in the lung.
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13. SUGGESTIONS FOR FURTHER WORK
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13.1 Acute Severe Asthma
Recruiting greater numbers of subjects may reveal a significant difference in 
ACE genotype distribution between asthmatics and controls. As plasma 
angiotensinogen may be the rate-limiting factor in the formation of angiotensin II it 
would be worth measuring this in acute asthma as it is elevated in acute inflammation 
and in response to corticosteroid administration. Angiotensinogen is also increased in 
response to oestrogens and it would be interesting to measure angiotensinogen levels in 
female asthmatics who have pre-menstrual deterioration of their asthma control.
Another possible reason for activation of the renin-angiotensin system in asthma 
may be to counteract the vasodilator effects of other mediators such as bradykinin. It 
would be interesting to measure bradykinin in acute asthma and to compare this with 
renin and angiotensin II.
Although it is known that circulating angiotensin II is raised in acute asthma, it 
is not clear whether this reflects the local milieu in the airway wall. It would be 
interesting to obtain induced sputum from asthmatic subjects and to examine the 
supernatant for angiotensin II to find out if this is reaching the epithelial surface of the 
airway or is generated locally.
13.2 Challenge Studies
Angiotensin II can enhance the bronchoconstrictor effects of methacholine but 
not histamine in the human asthmatic airway. Endothelin-1 is another potent 
bronchoconstrictor and angiotensin II can potentiate its effects in vitro in bovine 
bronchial rings. It would be valuable to investigate the effect of infused angiotensin II 
on endothelin-1-induced bronchoconstriction in human asthmatics.
Exercise is known to stimulate the renin-angiotensin system and also to be a 
trigger for asthma. Comparison of plasma renin and angiotensin II levels in response to 
exercise challenge in asthmatics and non-asthmatic controls would be of interest. The 
response of the renin-angiotensin system to allergen challenge in sensitive individuals is 
not known and would be worth exploring further.
If any clinically relevant elevation of renin and angiotensin II is found then 
attempts to attenuate these changes by pre-treatment with ACE inhibitors or angiotensin 
II receptor antagonists may prove to be of therapeutic benefit.
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Although intravenous angiotensin II is known to have bronchoconstrictor 
properties, the effect of inhaled angiotensin II on both the normal and asthmatic airway 
is not known. It would be interesting to compare this with known bronchoconstrictors 
and to elucidate whether any effect on the airway was irritant or receptor-mediated by 
using angiotensin II receptor antagonists.
Previous studies have demonstrated elevation of renin and angiotensin II in 
asthmatics in response to inhaled and intravenous salbutamol, however the effects of 
this in healthy non-asthmatic volunteers has not been studied.
13.3 In  V itro  Bronchial Reactivity Studies
In the light of my findings regarding the discrepancy between the effects of 
angiotensin II on methacholine and histamine it would be useful to re-examine the 
mechanism of potentiation in vitro in human bronchial rings; in particular, clarifying if 
this is a receptor-mediated phenomenon using type-1 and type-2 angiotensin II receptor 
antagonists. Further teasing out of the second messenger pathways involved could be 
done using phorbol esters, charybdotoxin, cholera toxin and specific inhibitors of the 
arachidonic acid pathway such as indomethacin and newer cox-2 selective inhibitors 
such as meloxicam.
Angiotensin II is known to enhance the effect of endothelin-1 on bovine 
bronchial rings in vitro, but this has not been studied on human bronchi as yet.
Another angle to the in vitro work would be to add angiotensinogen and 
angiotensin I to the organ baths and look for any signs of bronchoconstriction and 
measure angiotensin II levels in the bath fluid, which would indicate local formation of 
angiotensin II by ACE or protease enzymes.
13.4 Airway Remodelling
It would be of value to confirm the effects of angiotensin II on human airway 
smooth muscle cell growth in vitro and to compare this with its effects, if any, on rat 
airway smooth muscle in vitro. The use of specific angiotensin II receptor antagonists 
would elucidate whether this was a type-1 or type-2 effect. In view of the potentiating 
effects of angiotensin II on bronchoconstriction it would be interesting to study its 
mitogenic effects in combination with other known growth promoters such as 
histamine, endothelin-1, PDGF and leukotrienes.
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Although my studies of airway remodelling in rats were negative it would be 
worthwhile repeating these experiments in a model of airway inflammation such as 
sensitising rats or guinea pigs to ovalbumin then infusing angiotensin II. If epithelial- 
derived mediators are antagonising the effects of angiotensin II then stripping of the 
epithelium to mimic the pathological changes of asthma may be helpful. If a successful 
model were developed other growth promoters could be studied either alone or in 
combinations.
Finally, obtaining bronchial biopsies from asthmatic subjects would give some 
measure of cell turnover in the airway wall by using immunocytochemistry to detect 
proteins expressed by replicating cells such as proliferating cell nuclear antigen, Ki67 
and histone gene expression. It would also be interesting to measure tissue ACE activity 
in bronchial biopsies from asthmatics and to compare this with normal controls.
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APPENDICES
APPENDIX 1
GREATER GLASGOW HEALTH BOARD 
THE WEST ETHICAL COMMITTEE
Form Of Consent For Patients/Volunteers In Clinical Research Project 
Brief Title of Project
The effect of acute severe asthma on the activation of the renin-angiotensin system and 
its relation to plasma salbutamol concentration, atopic status and circulating 
inflammatory mediators.
Patient's Summary (Purpose of study, nature of procedure, discomfort and possible 
risks in terms which the patient or volunteer can understand.)
We have found that a hormone called angiotensin II is elevated in the blood of 
patients during acute attacks of asthma. We have also shown that salbutamol (Ventolin) 
can cause increased levels of angiotensin II when given by a nebuliser or intravenously. 
In addition, we know that angiotensin II can cause narrowing of the airways when 
given intravenously and that other substances released by cells in response to 
inflammation during acute asthmatic attacks can also increase the levels of this 
hormone.
We are now interested in measuring the levels of angiotensin II, as well as the 
plasma levels of salbutamol and also several chemicals in the blood, which are raised in 
the inflammation occurring during an acute attack of asthma. We also wish to make 
similar measurements in patients who do not suffer from asthma for comparison.
We would be most grateful if you would permit a blood sample to be taken in 
addition to those routinely checked on admission to the Accident & Emergency 
Department. This would involve the removal of around lOOmls. of venous blood and 
3mls. of arterial blood to measure the blood oxygen level, in asthmatic patients only. 
You would also have your blood pressure measured and undergo a simple breathing 
test. A finger probe will be attached to one of your fingers to measure the oxygen level 
in the blood indirectly.
I f  you do wish to take part, your General Practitioner will be advised o f your 
participation and the clinical management you will undergo. It should be noted that your 
participation in this study may not be o f direct benefit to you, but could help develop 
treatment for the benefit o f future patients. I f  you do not wish to participate in this trial 
or wish to withdraw at any time after commencing the trial, you are free to do so and 
your normal care will not be affected. I f  you are pregnant or likely to become so, you 
should not take partin the trial.
Consent
I , ................................................ o f .....................................................................................
give my consent to the research procedures described above, the nature, purpose and 
possible consequences of which have been described to me b y ........................................
Signed.....................................................................  Date................
Witness..............................................................
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APPENDIX 2
ACE Genotyping Method
1. 5ml EDTA samples of blood were obtained from subjects and frozen until analysis.
2. The buffy coat was resuspended in nuclei lysis buffer (lOmM Tris-HCl, 400mM 
NaCl, 2mM Na2EDTA, pH 8.2) (244).
3. Cell lysates were digested overnight at 37°C with 0.2ml 10% SDS & 0.5ml protease 
K solution (1 mg protease K in 1% SDS & 2mM Na^DTA).
4. 1ml saturated NaCl (6M) was added then shake for 15 secs, and centrifuge at 2,500 
rpm for 15 mins.
5. Supernatant containing the DNA was removed and precipitated by adding 2 volumes 
of absolute ethanol.
6. Precipitated strands of DNA were removed and dissolved at 37°C for 2 hours in 
100-200)1L TE buffer ( lOmM Tris-HCl, 0.2mM Na^DTA, pH 7.5)
7. DNA was then diluted 10-fold to ensure approximately 50ng of template DNA per 
20|iL reaction volume.
8. Polymerase chain reaction was then performed according to the method of Rigat et 
al. (193). The reaction mixture contains 10 pmol of each of 2 primers:
i) Sense oligo 5’ CTGGAGACCACTCCCATCCTTTCT 3 ’
ii) Anti-sense oligo 5’ GATGTGGCCATCACATTCGTCAGAT 3’
in a final reaction volume of 50|_tL containing 3mM MgCl2, 50mM KC1, lOmM Tris- 
HC1 pH 8.4,0.1 mg/ml gelatin, 0.5mM of each dNTP (Pharmacia), 1 unit of Taq 
polymerase (Cetus). 10% Dimethyl-sulphoxide is also added to the reaction mixture 
to prevent the under-expression of I allele amplification in heterozygotes which can 
lead to mis-classification of the DD genotype.
9. DNA was amplified for 30 cycles with denaturation at 94°C for 1 min., annealing at 
58°C for 1 min. and extension at 72°C for 2 min. using a PTC-100 thermal cycler.
10. The PCR products were analysed by submarine agarose gel electrophoresis, then 
gels were stained with ethidium bromide and examined under ultraviolet light. The 
amplified product is 190bp for the deletion allele and 490bp in the presence of the 
insertion.
11. Samples identified as DD homozygotes were confirmed by re-analysis using the 3- 
primer method according to Evans etal. (174), using the following primers:
i) ACE 1 - 5’ CATCCTTTCTCCCATTTCTC 3 ’
ii) ACE 2 - 5’ TGGGATTACAGGCGTGATACAG 3 ’
iii) ACE 3 - 5’ ATTTCAGAGCTGGAATAAAATT 3’
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The reaction products were analysed by vertical polyacrylamide gel electrophoresis 
and stained with ethidium bromide. The amplified products are 84bp for the deletion 
allele and 65bp for the insertion allele.
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APPENDIX 3
GREATER GLASGOW HEALTH BOARD 
THE WEST ETHICAL COMMITTEE
Form Of Consent For Patients/Volunteers In Clinical Research Project 
Brief Title of Project
The effect of angiotensin II on histamine-induced bronchospasm in mild asthmatics.
Patient’s Summary (Purpose of study, nature of procedure, discomfort and possible 
risks in terms which the patient or volunteer can understand.)
We have found that a hormone called angiotensin II (All) is raised in the blood 
of patients during acute attacks of asthma and more recently have shown that when 
administered intravenously to mild asthmatics, All can cause narrowing of the airways. 
In this study we wish to determine whether low concentrations of All given 
intravenously can increase the effect of a substance called histamine. When inhaled as a 
mist in high enough doses, histamine causes bronchoconstriction rather like a mild 
asthma attack..
You are invited to visit the lab on 4 study days. On the first visit you will have a 
standard histamine challenge test. This will involve inhaling increasing concentrations 
of histamine to determine the dose that produces a mild wheeze. We shall measure this 
by breathing tests like those performed at clinics. This wheeze can easily be reversed by 
Ventolin. Each of the remaining 3 visits will last about 90 mins. On arrival we shall 
measure your breathing by asking you to blow into a tube. Then a needle will be 
inserted into a vein on each forearm for blood sampling & administration of All. After a 
short rest you will then receive a drip into the arm of either low dose All, higher All or 
placebo. At the time of the study neither your nor the doctor will know which one, to 
avoid bias. The drip will last for the duration of the study (approx. 60mins.) After 30 
mins. we will ask you to inhale the dose of histamine required to cause mild wheeze. 
Breathing tests will be performed every 5 mins. for 20 mins.
All is a hormone which will cause a rise in blood pressure. This effect is likely 
to be mild at the concentrations used in this study. We shall however take the precaution 
of monitoring your blood pressure during the study & stop the drip if this rise is 
thought to be unacceptable. Histamine may cause mild wheeze, cough or a tight feeling 
in the chest; this will be reversed by the Ventolin. Blood samples (30ml) will be taken at
0, 30 & 60 minutes, the total amount of blood taken being 120mls. per visit.
I f  you do wish to take part, your General Practitioner will be advised o f your 
participation and the clinicalmanagementyou will undergo. It should be noted that your 
participation in this study may not be o f direct benefit to you, but could help develop 
treatment for the benefit o f future patients. I f  you do not wish to participate in this trial 
or wish to withdraw at any time after commencing the trial, you are free to do so and 
your normal care will not be affected. I f  you are pregnant or likely to become so, you 
should not take part in the trial.
Consent
1 , ...............................................  o f .....................................................................................
give my consent to the research procedures described above, the nature, purpose and 
possible consequences of which have been described to me b y ........................................
Signed............................................................... Date......................
W itness..............................................................
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APPENDIX 4
Alkaline Phosphatase-Anti-Alkaline Phosphatase Immunocytochemistry
1. Tissue sections were de-waxed in xylene for 10 minutes, then hydrated to methanol.
2. Endogenous peroxidase was removed by treating in 0.5% hydrogen peroxide in 
methanol for 30 minutes.
3. Rinse in water for 15 minutes.
4. Wash in 0.05M Tris buffered saline (TBS).
5. Dry slides then delineate sections with a P.A.P. pen to prevent loss of applied 
antibody and lay slides on a tray.
6. Sites for non-specific binding were blocked by applying 20% normal swine serum in 
TBS for 15-20 minutes for polyclonal antibodies (use 2% bovine serum albumin for 
monoclonal antibodies).
7. Drain and wipe sections.
8. Apply the primary antibody 1:1,000 dilution and incubate overnight at 4°C.
9. Wash sections with TBS three times over 10 minutes.
10. Apply secondary antibody: Biotinylated anti-rabbit immunoglobulin from 
ExtrAvidin kit (DAKO) 1:250 dilution in TBS and pooled normal human serum 
(Sigma Chemicals, U.K.) 1:250 in TBS to prevent non-specific binding. Leave for 
30 minutes at room temperature.
11. Wash several times in TBS.
12. A third layer is applied of Streptavidin-antibody-alkaline phosphatase (biotinylated) 
[DAKO], diluted 1:110 in TBS, for 30 minutes at room temperature.
13. Wash in TBS as before.
14. Visualise using 3,3-Diaminobenzidine Tetrahydrochloride in Tris buffer for 5-10 
minutes.
15. Wash in water and check control sections.
16. Counterstain with a light haematoxylin nuclear stain.
17. Dehydrate, cover and mount.
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APPENDIX 5
Modification of Immunocytochemistry for Bromodeoxyuridine Staining
1. Dewax sections and treat with hydrogen peroxide, then rinse in water as above in 
Appendix 1.
2. Microwave on high power in citrate buffer for 10 mins. then stand at room 
temperature for 20 mins. This is to facilitate antigen retrieval from the tissue sections 
(245).
3. Wash well with tap water.
4. Digest in 0.1% trypsin and 0.1% calcium chloride in TBS at pH 7.6 for 2 minutes.
5. Wash well with tap water.
6. Incubate with 2% bovine serum albumin (BSA) in phosphate buffered saline (PBS) 
pH 7.6 for 10 mins. at room temperature then drain and wipe slides.
7. Treat with mouse monoclonal anti-BrdU antibody (Eurodiagnostics, UK) diluted 
1:20 in 2% PBS/2% BSA at 4°C overnight.
8. Wash with PBS several times over 15 mins., drain and wipe.
9. Treat with rabbit anti-mouse antibody-peroxidase conjugate diluted 1:20 in 2% PBS/ 
2% BSA for 30 mins. at room temperature (100 pL  per section).
10. Wash with PBS several times over 15 mins.
11. Visualise in diamino-benzidine (DAB) (450 mL PBS, 50 mL imidazole, 250 pL 
hydrogen peroxide, 2 mL DAB solution) for around 8 mins.
12. Lightly counterstain with haematoxylin and mount.
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APPENDIX 6
In  S itu  Hybridisation
1. Hydrate sections to phosphate buffered saline (PBS).
2. Remove surface proteins in 0.2N hydrochloric acid for 15 minutes then rinse in PBS
3. Remove lipids in 0.3% Triton X100 in PBS for 15 minutes then rinse in PBS.
4. Proteinase K (1 in 10 dilution in PBS) digestion (~200pL per slide) at 37°C for 15- 
45 minutes then rinse in PBS.
5. Fix in 4% Paraformaldehyde in PBS for 5 minutes then rinse in PBS
6. Prehybridise for 1 hour at 37°C in 2x standard saline citrate (SSC) / 50% formamide
7. Hybridise overnight at 42°C with digoxygenin-labelled riboprobe diluted 1 in 50 in 
hybridisation buffer (ImM Tris pH 7.0, lx Denhardt’s solution, 2x SSC, 50% 
formamide, 0.5% sodium dodecyl sulphate, 0.5% dextran sulphate, 0.25mg/ml 
denatured and sonicated salmon sperm DNA, and water for dilution) allowing 15 pL  
solution per coverslip. Remove coverslips in 4x SSC.
8. Wash in 2x SSC twice for 30 minutes at room temperature, then 0.1% SSC for 10 
mins. at room temperature, then 0.1% SSC for 30 mins. at 37-45°C, then 0.1%
SSC for 20 mins. at room temperature.
9. Apply Digoxygenin buffer 1 ( lOOmM Tris HC1, 150mM sodium chloride at pH 7.5, 
20°C) for 5 minutes.
10. Apply Digoxygenin antiserum for 2 hours (diluted 1 in 2,000 in Digoxygenin buffer 
1 and 10% normal rat serum).
11. Wash in Digoxygenin buffer 1 twice for 15 minutes.
12. Wash in Digoxygenin buffer 3 ( lOOmM Tris, lOOmM sodium chloride, 50mM 
magnesium chloride at pH 9.5, 25°C) for 5 minutes.
13. Apply 22pL nitro blue tetrazolium, 16.7pL 5-bromo, 4-chloro, 3-indolyl phosphate 
and 1.15mg levamisole in 5ml of digoxygenin buffer 3 and incubate at room 
temperature in a humid atmosphere away from direct sunlight.
14. Counterstain with haematoxylin, dehydrate and mount.
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APPENDIX 7
DNA Extraction and Riboprobe Preparation
1. Freeze-dried bacteria containing the plasmids with the DNA fragment of interest are 
reconstituted in medium containing an appropriate antibiotic.
2. 2ml of medium is inoculated with bacteria from a glycerol stock solution then grown 
for 8 hours at 37°C in a shaking incubator, then 0.5ml of this solution added to 10ml 
of medium and incubated as above, then this is added to 400ml of medium and 
incubated overnight.
3. The bacterial growth is centrifuged in 500ml polycarbonate tubes at 6000 rpm for 30 
minutes at 4°C in an Ultra centrifuge using the JA10 rotor.
4. Supernatant is discarded and bacteria resuspended in Qiagen buffer PI (50mM 
Tris/HCl, lOmM EDTA pH 8.0, 100pg/ml RNAse A)for 5 minutes at room 
temperature.
5. Add 10ml of Qiagen P2 buffer (200mM sodium hydroxide, 1% sodium dodecyl 
sulphate), mix gently and stand for 5 minutes at room temperature.
6. Add 10ml of chilled Qiagen P3 buffer (3M potassium acetate, pH 5.5), mix and 
stand on ice for 15 minutes.
7. Centrifuge at4°C for 30 minutes at 17,000 rpm, remove supernatant, spin again and 
retain supernatant.
8. Equilibrate Qiagen Tip-500 with 10ml of Qiagen QBT buffer (750mM sodium 
chloride, 50mM 4-MorpholinePropaneSulfonic acid[MOPS], 15% ethanol, 0.15% 
Triton X-100 at pH 7.0) by allowing tip to empty by gravity.
9. Pour supernatant into tip and allow to empty.
10. Wash Tip-500 twice with 30ml of Qiagen QC buffer (1.0M sodium chloride, 50mM 
MOPS, 15% ethanol at pH 7.0).
11. Elute plasmid DNA with 15ml Qiagen QF buffer (1.25M sodium chloride, 50mM 
Tris, 15% ethanol at pH 8.5) and collect.
12. Precipitate DNA with 0.7 volumes of isopropanol for 5 minutes at room temperature
13. Centrifuge at 4°C for 30 minutes at 12,000 rpm to produce a pellet of DNA.
14. Pour off supernatant, add 2ml of 70% ethanol, centrifuge at 4°C for 30 minutes at 
13,000 rpm then pour off supernatant.
15. Air dry for 5 minutes, then resuspend in 200-400(11 of distilled water.
16. If necessary the DNA fragment can be cut from the plasmid and subcloned into a 
more suitable plasmid with more appropriate restriction sites.
17. Linearise plasmid using an appropriate restriction enzyme to cut the plasmid at the 
desired site. Set up reaction in an autoclaved ICC tube containing 2|il of reaction
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buffer, l |ig  plasmid, 2pl restriction enzyme and DEPC-treated water to a total 
volume of 20jil. Allow to digest for 2 hours at 37°C in a water bath.
18. Add 280(il water and 300pl phenol / chloroform, mix by vortexing for 30 seconds, 
then centrifuge for 30 seconds at 13,000 rpm.
19. Remove and retain the upper aqueous phase, add 300pl chloroform, mix and spin 
as above, then repeat once more.
20. Remove and retain the aqueous phase, add 0.5ml ice cold 100% ethanol and lp l of 
glycogen / 2.5M sodium acetate, allow to precipitate DNA for at least 1 hour to 
overnight.
21. Centrifuge at4°C for 15 minutes at 13,000 rpm, remove supernatant, replace with 
70% ethanol and repeat.
22. Pour off excess alcohol, air dry and reconstitute in 20|il water.
23. Nature and purity of the plasmid can be checked on an agarose gel.
24. Riboprobes (single-stranded RNA, either sense or anti-sense) are produced by 
setting up the reaction solution in an autoclaved ICC tube as follows: 4|il of 
transcription buffer, 2fil 1-4-Dithiothreithol, 2pl nucleotide tri-phosphate mix (2(il 
ATP, 2 j l x 1 CTP, 2pl GTP, lp l UTP [all lOOmmol], 5.41pl Digoxygenin-11-UTP 
[lOmmol], 7.59pl water), 2pl linearised plasmid, 0.5pl RNAse inhibitor (500 
units/ml), 7.5pl water and 2(il RNA polymerase (40 units) as appropriate for the 
restriction sites. All reagents must be added in this order. Incubate at 37°C for 4 
hours in a water bath.
25. Stop the reaction and precipitate with ethanol and glycogen as above, wash with 
70% ethanol, pour off supernatant, air dry and reconstitute in 20pl water. Riboprobe 
can be frozen until required.
ALL water, solutions, glassware, tubes, etc. to be used should be pre-treated with
0.2% Diethyl Pyrocarbonate (DEPC) [Sigma D-5758].
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APPENDIX 8
RNA Extraction From Tissues and Northern Blot Analysis
1. Frozen tissue samples, 100-350 mg weight, are homogenised by adding lmL of 
TRIzol reagent (Life Technologies) per 100 mg tissue, then mixing in a glass mortar 
and pestle and incubate at room temperature for 5 mins.
2. Add 0.2 mL chloroform per 2 mL of homogenate, cap tube, shake vigorously, 
incubate at room temperature for 2-3 mins. then centrifuge at 12,000 g for 15 mins. 
at4°C.
3. Transfer the upper colourless aqueous phase to a fresh tube, add 0.5 mL of 
isopropyl alcohol per 1 mL TRIzol reagent and incubate at room temperature for 10 
mins.
4. Centrifuge at 12,000 g for 10 mins. at 4°C. The RNA precipitate forms a white- 
yellow pellet at the bottom or side of the tube.
5. Remove the supernatant and wash once with 75% ethanol (1 mL per mL of TRIzol 
reagent used initially), mix by vortexing then centrifuge at 7,500 g for 5 mins. at 
4°C.
6. Allow pellet to air dry, but not completely then reconstitute the RNA pellet in 100 pih 
of DEPC-treated water, vortex briefly then incubate for 10 mins. at 60°C to ensure 
dissolution.
7. Prepare agarose gel by microwaving 0.6 g of agarose in 43.75 mL of DEPC-treated 
water for 2 mins. on full power. Cool slightly then add 2.5 mL 20x MOPS buffer 
(see appendix 4) and 3.75 mL formaldehyde. Mix gently and cool to about 60°C. 
Pour 20 mL into minigel apparatus and allow to set.
8. Prepare samples by heating 10 piL of RNA solution with 10 piL of sample buffer (5x 
MOPS, formamide, 10% formalin, and loading buffer [ethidium bromide and 
bromophenol blue dye]) at70°C for 15 mins. then cool on ice for 15 mins.
9. Cover the agarose gel with lx MOPS and load 10-20 yCL of prepared sample into 
each well on the gel. Set electrophoresis at 0.12 kV / 42 mAmps for 2 hours until the 
front reaches the middle of the gel.
10. Wash the gel in 20x SSC for 10-15 mins.
11. Pre-soak the nylon membrane (Hybond-N+, Amersham, UK) in 20x SSC
12. Place 1 litre of 20x SSC in a large rectangular dish, put a support in the base of the 
dish and cover with 2 pieces of 3MM filter paper (Whatman, UK). Place the gel on 
top of this with the lower surface uppermost.
13. Place a piece of the nylon membrane on top of the gel and roll a pipette over the 
surface to expel any bubbles and ensure a good contact.
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14. Cut 3 pieces of 3MM filter paper to size, wet two and cover the membrane then 
place the third piece on top and then put several paper towels (3cm thick) on top of 
this.
15. Seal with cling film to prevent drying and weight the whole assembly with a glass 
plate and a 500g weight to compress and leave overnight.
16. The membrane is removed, allowed to air-dry, then placed between two sheets of 
filter paper and baked at 60°C for 1 hour.
17. Rehydrate blot in 20x SSC.
18. Make up a small plastic bag around blot and add pre-hybridisation buffer (5x SSC,
0.5% sodium dodecyl sulphate (SDS) & 5x Denhardt’s solution) and incubate for
1.5 hours at 50°C.
19. Dilute labelled riboprobe to be used in pre-hybridisation buffer to give a 
concentration of InM.
20. Remove old buffer from sealed bag and add fresh buffer containing labelled probe, 
reseal bag and incubate overnight at 50°C.
21. Cut open bag and wash filter twice for 10 mins. at 50°C in lx SSC/0.5% SDS, then 
twice for 10 mins. at 50°C in 0.25x SSC/0.5% SDS, then for 5 mins. in lx SSC at 
room temperature.
22. Wash blot in digoxygenin buffer 3 (see appendix 3) for 5 mins. then transfer blot to 
nitro blue tetrazolium/5-bromo,4~chloro,3-indolyl phosphate dye solution, cover 
with aluminium foil and incubate until bands are visible (1-2 hours). A digoxygenin- 
labelled RNA ladder is run with the samples to allow sizes to be compared.
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APPENDIX 9
Iodination of Sarcosine1-Angiotensin II (Saralasin)
1. Sarcosine1-angiotensin II (saralasin) [Peninsula Labs., USA], Iodogen (Pierce, cat 
no.28600X) and 125I' radio-iodine are mixed in the ratio of 2: 0.75: 1 moles in a total 
volume of 120 piL of 20 mM phosphate buffer at pH 7.5. The iodogen must be 
prepared shortly prior to use due to its instability and will convert iodide to iodine 
which will substitute into a tyrosine ring on the saralasin peptide.
2. Incubate the vial for 30 mins. at room temperature, mixing every 5 mins.
3. Add 120 piL of 0.2M triethanolamine buffer pH 8.5 to terminate the reaction.
4. Radiolabelled peptide is extracted by high performance liquid chromatography 
(HPLC) using a reverse-phase silica column 250 x 4.6mm, 5 ptm C18 (Sigma- 
Aldrich). Flush column with acetonitrile.
5. Equilibrate column for 30-60 mins. with 0.1M triethanolamine pH 8.5 at 1.0 
mL/min.
6. Inject the initial incubation sample containing labelled peptide.
7. Collect first 15 mL of effluent into a flask, then collect and retain 60 aliquots of 333 
piL fractions into tubes containing 166 ptL of methanol (i.e. one fraction every 20 
seconds). Finally collect about 100 mL into another flask. The elution volume of the 
labelled peptide is about 20 mL (around fraction 30).
8. The fractions containing the highest radioactivity are identified by scanning the tubes 
of effluent with a hand-held gamma detector. Plot the radioactive content against 
fraction number to identify the fractions with the labelled probe.
9. The five fractions with the peak radioactivity after the peak fraction are pooled in a 
10 mL glass tube and 10 ptmdi of benzamidine hydrochloride is added.
10. The volume is reduced to 0.1-0.2 mL by evaporation under a stream of dry, filtered 
air (or nitrogen) at room temperature.
11. Add 0.8 mL of methanol, seal and vortex then store at -20°C until use.
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APPENDIX 10
Angiotensin II Receptor In  Situ  Autoradiography
1. Warm frozen tissue sections to room temperature.
2. Rehydrate tissue sections in Tris/NaCl buffer (see below) for 10 minutes at 4°C. 
Tris/NaCl buffer Tris 50mM, NaCl 120mM, MgCl2 12.5mM, benzamidine HC1 
12.5mM and NaN3 0.025% (w/v) pH 7.4.
3. Shake off excess liquid from slides.
4. Apply radiolabelled saralasin, 120pL per cm2, in assay buffer (see below) at a 
concentration of 10 nM which produces virtually maximal receptor binding.
Assay buffer: Tris 50mM, NaCl 120mM, MgCl2 12.5mM (Mg2+ increases 
angiotensin binding in some tissues), benzamidine HC1 12.5mM (an endopeptidase 
inhibitor; Sigma), acitonin 0. ImM (an aminopeptidase inhibitor; Peninsula), bestatin
0. ImM (an aminopeptidase inhibitor; Peninsula), bacitracin 0.3mg/mL (a peptide 
antibiotic which inhibits various enzymes; Sigma) and BSA 0.5% (w/v) pH 7.4 
(prevents non-specific adsorption of the radioligand; Sigma).
5. Add 400 pM  unlabelled angiotensin II to a final concentration of 10 pM  to block 
receptors in the tissue section for non-specific binding.
6. Add Dup753 (Losartan, DuPont) in a concentrated solution to a final concentration 
of 10-20 pM to block AT! receptors on tissue sections to show AT2 receptor 
binding.
7. Add PD123319 (Parke Davis) in a concentrated solution to a final concentration of 
10-20 pM  to block AT2 receptors on tissue sections to show ATX receptor binding.
8. Incubate all slides for 60-75 minutes at 22°C in a humidified chamber.
9. Rinse off incubation solution with Tris/NaCl buffer at 0-4°C to remove unbound 
ligand.
10. Wash three times for 5, 5 & 10 minutes in Tris/NaCl containing 0.1% (w/v) bovine 
serum albumin (BSA) and 0.1% (v/v) Tween 20 at 0-4°C.
11. Wash once for 5 minutes in Tris/NaCl buffer at 0-4°C.
12. Sections for film autoradiography should be dipped in cold (0-4°C) distilled water to 
remove soluble material then dried in a stream of air. The sections are now ready for 
film exposure as described in chapter 4.
13. Sections for emulsion coating are dipped in cold water, then incubated in cold (0- 
4°C) phosphate buffered saline (PBS) pH 5.0 containing 12.5 mM MgCl2 for 10 
minutes to rinse off Tris buffer.
14. Incubate sections overnight in a humidified container at 2°C with PBS pH 5.0 
containing 12.5 mM of MgCl2 and 0.5M EDAC cross-linking agent (EDAC = 1-
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ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (Sigma, cat no. E- 
7750).
15. Incubate sections in PBS pH 3.0 containing 0.1% (w/v) BSA and 0.1% (v/v)
Tween 20 for 90 minutes at room temperature.
16. Rinse in water to remove any non-covalently bound radioligand.
17. Fix sections in formalin or glutaraldehyde if required then rinse in water.
18. Rinse slides in alcohol and dry in a stream of air.
19. In a dark-room, warm the emulsion (Amersham LM-1) to 43°C and stir slowly to 
obtain a uniform consistency then pour into a dipping vessel.
20. Slowly dip each slide into the emulsion for 4 seconds then remove slowly.
21. Wipe off excess emulsion from the back of the slide and leave to stand vertically on 
paper tissue for at least 20 minutes at room temperature to allow excess emulsion to 
run off.
22. Pack slides into boxes maintaining the vertical orientation for about one hour to 
ensure a uniform film of emulsion over the sections then transfer to a refrigerator 
(~4°C) to expose for 96 hours (Time varies with amount of activity per section).
23. Equilibrate slides to room temperature then develop in Kodak D19 developer 
(Sigma) for 6 minutes, fix in GBX fixer (Sigma) for 12 minutes, then dip in water to 
remove processing chemicals.
24. Lightly counterstain if required in haematoxylin and mount.
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